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Myotonic Dystrophy type I (DMl) is caused by muscleblind protein sequestration
to aberrantly expanded CUG repeats. When muscleblind is sequestered it can no longer
fulfill its role as an alternative splicing regulator, leading to mis-splicing events in both
humans and Drosophila. The nmscleblind protein family's RNA binding specificity has
been minimally characterized. Only one pre-mRNA target in humans, cardiac troponin T
(cTNT), has a known MBNLI binding site. In order to understand muscleblind's RNA
binding specificity and identify a consensus binding motif, systematic evolution of
ligands by exponential enrichment (SELEX) was performed on both the Drosophila
muscleblind protein, Mbl, and the human ortholog, MBNLI.
Drosophila has provided a useful model for studying the disease mechanism of
DMI. Studies of Mbl's RNA binding specificity to CUG repeats concluded that
replacing the U-U mismatches with different pyrimidine-pyrimidine mismatches was
tolerated, but no other mutations were. To understand Mbl's RNA binding specificity,
SELEX was performed. After 6 rounds, several sequences were identified that bound
with high affinity, all containing the 5'-AGUCU-3' consensus motif. One sequence,
SELEX RNA 20 was analyzed further. In addition to the guanosine in the consensus
motif of SELEX RNA 20, two other guanosines were shown to be protected by Mbl in a
footprinting assay, indicating that Mbl has a strong preference for binding guanosine.
Also, two "tail" regions of SELEX RNA 20 were shown to be single stranded and
required for binding by Mbl. These results indicate that Mbl is a highly specific RNA
binding protein with preference for both single and double stranded guanosine-rich
regIOns.
A doped SELEX was performed on MBNLI 's binding site from the cTNT pre-
mRNA to determine which sequences and structural aspects were important for
recognition by MBNLI. Pool 5 RNA sequences bound with high affinity, and the motif
5'-YGCUU-3' was selected. This motif was then used to identitY new MBNLI binding
sites in pre-mRNAs regulated by MBNLI, SERCAI and MBNLl. The identification of
this motif and two new MBNL I sites provide insight into MBNL I-mediated alternative
splicing.
This dissertation includes both my previously published co-authored material and
my unpublished co-authored material.
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1CHAPTER I
INTRODUCTION
According to the central dogma of biology, DNA codes for the functioning units
of the cell, proteins. RNA acts as the intermediate, transferring information from the
genes encoded in the DNA to create the diverse set of proteins that carry out the majority
of the work needed by the cell. RNA is an unstable molecule and is heavily protected by
a host of proteins that prevent its degradation. Although typically regarded as an
intermediate, RNA is as powerful as protein and DNA in that it can compose a viral
genome, regulate the translation of protein and can even be a catalyst, such as catalyzing
the reactions necessary for splicing.
Splicing occurs co-transcriptionally, with a specifically orchestrated series of
events transforming pre-messenger RNA, pre-mRNA, into mRNA. In most cases, the
intron is initially recognized and bound by the U1 small nuclear RiboNucleoProtein (U1
snRNP), splicing factor 1 (SF1), and U2 auxiliary factor (U2AF), together termed E
complex. U2 snRNP then replaces SF1 bound to the branch point sequence, termed A
complex. The transition from E complex to A complex is ATP dependent. U1 snRNP is
then replaced by the U4/U5/U6 tri-snRNP at the 5' splice site, termed B complex. C
complex occurs next and includes the two transesterification reactions necessary for
ligation of the two exons. The 2' hydroxyl group from the branch point adenosine attacks
2the phosphate in the guanosine at the 5' splice site. The 3' hydroxyl from the recently
freed exon attacks the 3' splice site of the second exon and ligates the two exons together.
This continues until all exons are ligated to form the mRNA (reviewed in refs 1 and 2).
In addition to the spliceosomal complexes, other regulatory factors, termed
alternative splicing factors, playa role in choosing which exons to include and which to
exclude from the final mRNA. There are several ways to alternatively splice a pre-
mRNA: cassette exons, mutually exclusive exons, alternative 5' and 3' splice sites,
alternative promoters, alternative poly(A) sites, and intron retention (reviewed in ref 3).
The job of an alternative splicing factor is to aid in splice site choice. Specific binding
sites in the pre-mRNA, in addition to other protein and structure factors, communicate
with alternative splicing factors to help with splice site decisions. The complexity of
alternative splicing regulation has made it difficult to identify many alternative splicing
regulators, much less understand the underlying mechanisms through which they operate.
This dissertation addresses this exciting, active field of research by analyzing
muscleblind, an alternative splicing regulator involved in myotonic dystrophy.
MYOTONIC DYSTROPHY
Myotonic Dystrophy falls under the category of muscular dystrophy, a general
term for over forty diseases characterized by muscle wasting. There are two types of
myotonic dystrophy, type I (OM!) and type 2 (DM2). They have many overlapping
symptoms with only subtle differences, such as the age of onset and group of muscles
affected. OM! has a rare, congenital form and is also the most common form of adult-
3onset muscular dystrophy while DM2 has no congenital form and is much less common
(4). Also, DMI symptoms include distal skeletal muscle degeneration at onset while
DM2 include symptoms of proximal skeletal muscle degeneration (5). Both diseases
have seemingly unrelated symptoms including myotonia, muscle wasting, insulin
resistance, cardiac abnormalities and iridescent cataracts. In 1992, DMI patients were
identified as having abberant CTG expansions in the dystrophia myotonica protein kinase
gene (DMPK) and in 2001 DM2 patients were identified as having abnormal CCTG
expansions in the first intron of the zinc finger 9 gene (ZNF9) (6, 7). Normal individuals
have a smaller number of CTG and CCTG repeats, 5-37 and less than 75, respectively (6,
7). In DM1, the age of onset and severity of symptoms are linked to the number of
repeats. Patients that develop DMI as adults have around 100 repeats or less, patients
that develop DMI as young adults or children have up to 500 repeats while congenital
cases are the most severe and have approximately 1000 repeats (8). DM2 patients
usually have an average of 5000 repeats even though the disease is less severe than DMI
(9). The commonalities between the two diseases most likely stem from an RNA gain of
function disease mechanism. Both repeats occur in non-coding regions, ruling out mutant
protein expression as causing the diseases, which is the case with many triplet repeat
diseases. Although there are some alterations in DMPK expression post-transcriptionally
and the expression of a nearby gene (SIX5) is affected, these changes do not appear to
playa large role in the disease mechanism because knock out mouse models of DMPK
and SIX5 display only two of the symptoms of DMI (10-14). In addition, changes in
levels of DMPK and SIXS expression cannot explain the same set of symptoms in DM2
as the repeats are in different locations.
4Although levels of DMPK protein and trancripts are not the main culprit in DM1
patients, DMPK transcripts containing the aberrant CUG repeats accumulate in the
nucleus of DM1 cells (15-17). Many proteins have been identified to co-localize or bind
to the aberrant DMPK transcript, however, muscleblind is the most prevalent and prefers
long CUG repeats (>20) over short (:s; 11) (18-20). Interestingly, muscleblind is a zinc
finger protein that binds RNA and regulates alternative splicing (21). The proposed
disease mechanism is that the expanded CUG repeats of the mutant DMPK transcript act
as muscleblind binding sites and compete with muscleblind's normal RNA binding
targets and sequester muscleblind to the expanded CUG repeats, which are observed as
nuclear foci (22, 23). The DMPK transcript/MBNL foci are transient, with a portion of
mobile MBNL and a portion of immobile MBNL, however, enough MBNL is
sequestered to cause abnormal splicing events (21). These aberrant splicing events lead
to symptoms of DM1 (Figure 1). This model is supported by a mouse knockout of
MBNL1 in which the mice display symptoms of myotonia, cataracts and splicing defects,
all of which are seen in DM1 patients (24).
Many transcripts have shown a dependence on MBNL1 for proper alternative
splicing (reviewed in (4)). Alternative splicing accounts for the high level of protein
diversity in humans, with over half the genes predicted to be alternatively spliced (3).
Alternatively spliced transcripts require an elevated level of regulation because
expression at the incorrect time or tissue may result in deleterious effects, including
disease. Muscleblind regulates its pre-mRNA targets in a developmentally specific and
tissue specific fashion, with its expression and nuclear localization corresponding
5Figure 1. A disease model for myotonic dystrophy type 1. The nucleus of a DMI
patient cell is shown as the dark gray circle and the cytoplasm as the light gray circle.
The stem structure in the nucleus represents aberrant CUG repeats that form stem-loops
and sequester muscleblind. In the cytoplasm, MBNL binds a pre-mRNA transcript; the
boxes represent exons and the black line, introns. In this example, MBNL binds
upstream of the central exon and promotes exclusion. When MBNL is sequestered, it
cannot promote exon exclusion and an aberrant transcript, labeled "aberrant", would be
translated. MBNL can also promote exonic inclusion as well.
6to the post-natal development stage (25). MBNLI regulates the alternative splicing of
insulin receptor (IR) and chloride ion channel (CIC-l) transcripts, both of which are mis-
regulated in DMI patients (26-28). One isoform of IR, IR-B, is expressed in skeletal
muscle and is responsible for binding insulin and aiding in glucose homeostasis. In DMI
patients, isoform IR-A is expressed which has a higher affinity for insulin, but a
decreased signaling ability. The expression of IR-A in adults instead of IR-B leads to the
symptom of insulin resistance in DMI (28). CIC-l is similarly mis-spliced with a
truncated or non-functional form of CIC-l expressed in DMI patients. CIC-l is
responsible for maintaining chloride ion channels and regulating' action potentials in
muscle tissue (26). The main cause of myotonia, the inability to relax a contracted
muscle, in DMI patients is thought to arise from the hyperexcitability of muscle fibers
leading to involuntary contractions. This is most likely a direct result of MBNLI no
longer regulating the proper splicing of CIC-l. Some evidence indicates that muscleblind
in Drosophila also regulates splicing in a similar development and tissue-specific manner
as MBNLl, as discussed in "the myotonic dystrophy type 1 Drosophila model" section.
A second alternative splicing regulator, CUG binding protein, CUG-BP, has been
identified as regulating many of the same pre-mRNAs as MBNLl, including CIC-l and
IR (26, 28). MBNLI and CUG-BP act antagonistically on many of the transcripts they
regulate; when MBNLI promotes exon inclusion, CUG-BP promotes exon exclusion and
vice versa (see section on "alternative splicing regulation mechanisms"). CUG-BP has
been implicated in the disease mechanism of DMI as levels have shown to be increased
in DMI cells. This increase in CUG-BP could account for some of the mis-splicing
7events (18, 28, 29). Evidence suggests that MBNLI is the dominant player in DMI
because over-expression of MBNLI in tissue culture is able to rescue many of the
splicing defects seen in DMl. However, siRNA of CUG-BP has a milder rescue effect
(18). Plus, it is controversial whether CUG-BP levels are in fact increased in DMI
patients.
Mis-splicing events are thought to be the main cause of DMl, with the partial list
at 24 known mis-spliced transcripts (30). Symptoms of myotonia and insulin resistance
have been accounted for by mis-splicing events, however, many symptoms remain
unaccounted for. Other mis-splicing events will likely lead to symptoms of muscle
wasting, iridescent cataracts, cardiac abnormalities and testicular atrophy. The full list of
MBNLl-regulated transcripts is yet to be completed, but is likely to be extensive.
ALTERNATIVE SPLICING REGULATION MECHANISMS
Alternative splicing is involved in a host of cellular processes, including
development, cell specificity and even sex determination. There are multiple
mechanisms in which an alternative splicing factor can regulate these processes. In one
mechanism, alternative splicing factors act by blocking splicing factors from binding to
regions of the intron that are important for splicing. The polypyrimidine tract, the branch
point sequence and the splice sites are all key binding sites for spliceosomal proteins.
Also, recognition of intronic/exonic splicing enhancers (lSE's, ESE's, respectively) and
intron/exonic splicing silencers (ISS's and ESS's, respectively) are essential for proper
alternative splicing of many pre-mRNAs. For example, Sex lethal, Sxl, in Drosophila
8binds an ISS in the polypyrimidine tract and the 5' splice site in an intron of the Mxl2
transcript. By binding in those regions, Sxl blocks both the binding of U2AF and the
binding of TIA-l, a regulatory factor, to the 5' splice site. These simultaneous blocking
events inhibit splicing of the first intron and eventually halt translation of the Mx12
mRNA (31). The downstream effect in males, where Sxl is not expressed, is expression
of Msl2 which regulates X chromosome dosage compensation. It is also possible for an
alternative splicing regulator to act positively and recruit other splicing factors.
A second mechanism of alternative splicing regulation is for an alternative
splicing regulator to act in conjunction with a cis-acting factor, such as secondary
structure, within the pre-mRNA target. Little is known about this type of mechanism, but
there is speculation that splicing factors c~m act to alleviate or promote secondary
structure and thus promote or prevent, respectively, other splicing factors to bind. For
example, the B-tropomyosin pre-mRNA has been shown to have a pair of stem-loops in
the exon and the polypyrimine tract that prevent inclusion of the exon. However, when
mutations abolish the stems, the exon can be recognized and included in the mRNA (32).
It is possible that alternative splicing regulators are involved in destabilizing the stem in
order to promote exon inclusion.
An example of secondary structures working with trans-acting factors to regulate
splicing is the RBMY protein. The RBMY protein in humans is an active alternative
splicing regulator in the testis and has been shown to bind with high affinity to a specific
stem-loop sequence and stabilize it in vitro. It is possible that RBMY can bind a stem-
loop in or near a regulated exon and stabilize the structure and prohibit binding by
9splicing factors that bind single stranded RNA (33). This type of regulation has also
been seen for the yeast protein RPL32 which regulates its own splicing. One of the
alternatively spliced exons contains a stem-loop structure that includes the 5' splice site.
L32 binds the stem-loop and most likely prohibits the binding of VI RNA (34). The
muscleblind family of proteins may act in a similar way by binding stem-loops near or
within the branch point sequence and/or the polypyrimidine tract and blocking binding of
splicing factors.
The binding site for MBNLI in cTNT pre-mRNA is a stem-loop about 35 bases
upstream of exon 5. MBNLI binds this site and promotes the exclusion of exon 5. The
stem forms on either side of the polypyrimidine tract, with the polypyrimidine tract in the
loop region. Mutations to abolish or strengthen the stem result in decreased binding
affinity of MBNLI to the site in vitro. Interestingly, the same mutations in a cTNT
minigene prevent MBNLI from regulating the splicing of exon 5 in tissue culture (21,
35). One set of mutations extends the length of the polypyrimidine tract and potentially
promotes the binding of V2AF, which would result in inclusion, instead of exclusion, of
exon 5. In contrast, when the wild type stem is in place and MBNLI is present, MBNLI
may bind and stabilize the stem-loop structure and prevent V2AF from binding. This
would promote exon 5 exclusion. However, more work needs to be conducted before this
mechanism can be established.
One proposed mechanism for how the muscleblind family of proteins may
regulate splicing is by binding upstream of the regulated exon to promote exon exclusion,
as seen in cTNT, and bind downstream to promote exon inclusion (21, 35). This type of
10
regulation has recently been shown for FOX-I and FOX-2 (FOX-I/2), another family
of tissue specific splicing regulators (36). Zhang et al. showed a clear bias in brain,
skeletal muscle and heart tissues for FOX-1I2 to repress exon inclusion when binding
sites were located upstream of the regulated exon, while sites downstream enhanced exon
inclusion. Nova is a neural-specific splicing regulator and acts very similarly to FOX-1I2.
Nova also displays this same pattern of regulation, when it binds downstream of the
regulated exon Nova acts as an enhancer and when bound upstream functions as a
repressor (37). This suggests that this class of regulatory splicing factors (FOX, Nova
and muscleblind) share a common mechanism through which to regulate alternative
splicing.
Alternative splicing regulators also can act on the same exon but one is a positive·
regulator while the other is a negative regulator. For example, MBNLI and eUG-BP
regulate several transcripts involved in DMI pathogenesis in this manner, including
cTNT exon 5. eUG-BP has been shown to bind several eUG motifs downstream of and
promote the inclusion of exon 5 (38). MBNLI, on the other hand, binds upstream of
exon 5 and promotes the exclusion of exon 5 (21). The two proteins act antagonistically,
when MBNLllevels are down, as in the case of DMI, exon 5 is included and the fetal
isoform of cTNT is aberrantly expressed (4). In DMI patients, exon 5 is aberrantly
included, consistent with MBNLI sequestration to eUG repeats. Levels of eUG-BP may
be increased in DMI, which could also lead to expression of the cTNT fetal isoform of
cTNT (38). Most likely, both proteins playa role in the pathogenesis of DMI, with
MBNLI being the dominant factor.
I 1
THE MUSCLEBLIND FAMILY OF PROTEINS
The muscleblind family of proteins are highly conserved and found in many, if
not all, metazoans but not in bacteria, fungi or plants. This indicates that muscleblind is a
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Figure 2. The muscleblind proteins are highly conserved, especially in the zinc
finger, RNA binding domains. Shown is an alignment of all four Drosophila
muscleblind splice isoforms (Mbl A-D) and the longest splice isoforms of the three
human muscleblinds, MBNLl, 2 and 3. The nlllnber of amino acids in each isoform is
displayed after the name of each protein. The zinc fingers are labeled below the
amino acids that compose them. The shading indicates regions of similar amino acid
identity. All seven proteins shown high sequence conservation for the first two zinc
fingers.
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relatively modern protein (39). Most invertebrates have only one muscleblind gene
while most vertebrates have three muscleblind genes. Muscleblind proteins are
composed of two to four zinc finger domains of the CCCH type. The spacing between
the cysteins and histidines varies from domain to domain, but in general, is either
CX7CX6CX3H or CX7CX4CX3H, X being any amino acid. Less complex species like
Drosophila, contain two zinc fingers, while more complex species, such as humans, have
four (Figure 2). It appears that a duplication event of the first pair of zinc fingers
occurred to produce genes with four zinc fingers. This is noticeable due to the similarity
of the 1st and 3rd zinc finger and the 2nd and 4th in MBNL1. Other domains such as the
LEV box, the NGR box, alanine-rich regions, phenylalanine rich regions and proline-rich
regions are moderately conserved but have unknown functions. There are multiple,
predicted phosphorylation sites throughout the muscleblind family of proteins, including
some conserved in the zinc finger domains. When phosphorylated, they could potentially
regulate the RNA binding function via steric hinderance (39).
The Drosophila muscleblind gene, Mbl, is expressed and spliced into 4 splice
isoforms, A-D. A-C splice isoforms have identical 179 N-terminal residues and contain
both the zinc fingers and are 203 amino acids, 316 amino acids, and 243 amino acids,
respectively. Splice isoform D is much shorter, only 84 amino acids, and contains 1.5
zinc fingers. Mbl C is likely the most ancestral splice isoform as homologs are found in
many other organisms (39). Mbl C is the most highly expressed throughout embryo,
larval and pupal stages, with Mbl B and A at slightly lower expression levels. Mbl D is
only expressed at the end of the larval stage and the beginning of the pupal stage. Mbl A,
13
Band D are not expressed in adult Drosophila, and C is moderately expressed in adults
(40). This expression profile is a sign that Mbl is involved in developmental processes as
discussed in "the myotonic dystrophy type I Drosophila model" section.
The human muscleblind-like proteins have multiple splice isoforms, MBNL1 has
9, MBNL2 has 3 and MBNL3 has 6 (20, 41, 42). The majority of splice isoforms of
MBNL1 contain all 4 zinc fingers, indicating that they are probably capable of binding
RNA. MBNL1 splice isoforms that contain only 0-3 zinc fingers are not capable of
binding RNA, according to a yeast 3 hybrid study (19). Similar to the expression pattern
of Mbl in Drosophila, mouse muscleblind-like proteins 1-3 are expressed throughout
development from 4.5 dpc to 18.5 dpc (42). Human muscleblind-like proteins 1 and 2 are
expressed in skeletal muscle, liver, placenta, brain, and heart tissues, with MBNL1 most
highly expressed in skeletal muscle. MBNL3 is only expressed in placental tissue, not
the other tissues tested (41). The differential expression patterns between MBNL1, 2 and
3 may indicate different roles, in addition to overlapping roles, for each of them. For
example, MBNL2 shuttles integrin <X 3 -mRNA to the required location in the cell
membrane for proper translation (43).
Drosophila have only one muscleblind gene, not three, so it is possible that the
four isoforms have some unique functions and some overlapping functions, similar to the
varied functions of MBNL1, 2 and 3. In a Mbl Drosophila knockout of Mbl, Mbl Cis
able to rescue the embryonic lethal phenotype while Mbl B and A can only partially
rescue the Mbl knockout. In addition, over-expression of Mbl C has the strongest effect
on <x-actinin alternative splicing. This indicates that the three isoforms are only partially
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redundant, with Mbl C fulfilling the main roles. Mbl A, Band C are expressed in both
the nucleus and cytoplasm of tissue culture cells with Mbl A preferentially expressed in
the cytoplasm and Mbl Band C preferentially expressed in the nucleus. Mbl A, Band C
all co-localize with CUG repeat RNA and form nuclear foci (40). It is possible that Mbl
C fills a similar role as MBNL1 in humans, regulating a developmental switch. Evidence
for this includes the ability of MBNL1 to rescue the lethal phenotype in Mbl knockout in
flies (44). Mbl A, on the other hand, may perform a similar role to MBNL2, as it is
primarily located in the cytoplasm and MBNL2 regulates the localization of integrin cx: 3-
mRNA in the cytoplasm (43). Overall, the Drosophila muscleblind splice isoforms and
the human muscleblind splice isoforms have very similar functions, if not identical.
THE MYOTONIC DYSTROPHY TYPE I DROSOPHILA MODEL
Muscleblind was first identified in a Drosophila genetic screen looking for genes
that are required for photoreceptor development and/or differentiation. In Mbl null flies,
deficient cells are recruited into developing ommatidia, begin early stages of
differentation but are unable to fully differentiate into terminal photoreceptors. This
indicates that Mbl is required for photoreceptor differentiation (45). Artero et al. showed
that muscleblind was also important for terminal muscle cell differentiation (46). Mutant
Mbl Drosophila are paralyzed, have contracted abdomen, lack striation of muscles and
die as embryos or in the early larval stage (46). This coincides with ubiquitous expression
of Mbl in the later stages of terminal muscle differentiation. Mbl was originally
hypothesized to be involved in transcriptional regulation and perhaps bind nucleic acids,
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but the function for its zinc finger domains was not known. Currently, Mbl has been
shown to bind RNA and regulate alternative splicing (8, 47, 48).
In DMl, the expanded CUG repeat RNA gains a toxic function by recruiting
MBNLI and causing symptoms of the disease. To investigate RNA sequestration of Mbl
in Drosophila, de Haro et al. created a Drosophila line that expresses 480 interrupted
CUG repeats (8). In this DMI Drosophila model, Mbl was sequestered to CUG repeats
in nuclear foci, there was muscle wasting and degeneration of indirect flight muscles,
disorganization and fusion of ommatidia and duplication or loss of bristles in the eyes.
These phenotypes are similar to DMI symptoms in humans of muscle wasting and
cataracts. In addition, over-expression of MBNLI relieved the eye phenotype while over- .
expression of CUG-BP enhanced this phenotype. This is similar to cTNT splicing events
in OMI tissue and cell culture. CUG-BP over-experession causes expression of the
developmentally incorrect isoform of cTNT while over-expression of MBNL allows for
expression of the proper cTNT isoform (21,38).
The Drosophila DMI model suggests that Mbl plays a similar functional role as
MBNLl, an alternative splicing factor. In fact, Mbl regulates the alternative splicing of
two transcripts shown to be regulated by MBNLl, ZASP and TNNT3 (47, 48). In
addition, Mbl is highly expressed throughout all pre-adult life stages, and expressed at
lower levels in adult Drosophila, indicating a role as alternative splicing regulator during
critical stages of development (40). Both of these transcripts, ZASP and TNNT3, are
mis-spliced in DMI patients, indicating that the mis-splicing may give rise to disease
symptoms. It is not surprising that Mbl and MBNLI play similar roles in the cell, as they
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are highly conserved, especially in the RNA binding domains which are involved in
the binding of the RNA and the regulation of splicing.
RNA BINDING SPECIFICITY OF MBNL TO CVG REPEATS AND OTHER
TARGETS
Muscleblind has only recently been discovered to be an RNA binding protein.
The first in-depth look at MBNLI 's binding to RNA and DNA was carried out by Kino et
al. (19). They show that MBNLI has a preference for binding RNA over DNA and that
binding is salt dependent, with NaCI concentrations of 250 mM or greater causing
disruption of the MBNLl/RNA complex. They used a yeast 3-hybrid assay and
confirmed that MBNLI prefers longer CVG repeats (16 +), over short repeats, as was
also seen in crosslinking experiments of MBNLI to CVG repeats (20). Interestingly,
MBNLI is capable of binding a CVG repeat of only 4, however this was achieved by
forcing a stem-loop conformation (35). This coincides with MBNLI having a preference
for binding longer CVG repeats because they are able to form stem-loops, whereas
shorter repeats are not (49).
A yeast 3 hybrid study showed that MBNLI binds CCVG, CCCG, CVVG and
CAAG repeats, with a preference for CCVG and CCCG repeats. These repeat RNAs are
capable of forming stems with mismatches. However, MBNL doesn't bind repeats, like
CVG 16/CAG16, that do not form mismatches (19). This was also seen in a mutational
screen of CVG repeats where various positions along the CVG repeat stem were mutated.
When the V-V mismatch was replaced with anything other than a pyrimidine-pyrimidine
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mismatch, such as a purine-purine mismatch, purine-pyrimidine mismatch, or Watson-
Crick base pairing, binding was significantly decreased. Changes in 5' to 3' orientation
and flipping the C-G base pair to a G-C base pair decreased MBNLl's binding affinity as
well (35). MBNLI is a specific RNA binding protein, with a preference for stem-
forming CUG repeats and pyrimidine-pyriminde mismatches. Because Mbl contains the
same RNA binding domains as MBNLl, analysis of the RNA binding specificity of Mbl
could give insight into endogenous binding sites for both MBNLI and Mbl.
DMPK transcripts with expanded CUG repeats are retained in the nucleus of
DMI patients and co-localize with MBNLI (22, 23). MBNLI binds double stranded
RNA and thus prefers to bind longer CUG repeats as they can form stem-loops easily.
The CUG repeat stem-loops are "slippery", with the sides of the stem sliding and creating
different registers. Also, the longer the CUG repeat, the more stable it becomes (49). It
is possible that MBNLI can bind and stabilize the stem. The CUG repeat stem consists of
two C-G base pairs interspersed with U-U mismatches in a relaxed, A-form state (49, 50).
This has been shown in the crystal structure of CUG repeat RNA and surprisingly the
presence of multiple U-U mismatches doesn't significantly alter the CUG repeat RNA
structure compared to the canonical A-form RNA structure. The six CUG repeat
structure reveals an accessible minor groove where MBNLI most likely interacts directly
with the U-U mismatches. In electron microscopy studies, MBNL binds to the middle
portion of the CUG repeat stem, not the loop or the base (51). On the other hand, CUG-
BP has been shown to bind near the base of CUG repeat stems most likely in the tail
region. This coincides with CUG-BP binding single stranded RNA (52). This supports
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the model that MBNLI co-localizes with long CUG repeats because they form double
stranded structures, while CUG-BP, which binds single stranded RNA, does not.
The sequestration of MBNLI to the CUG repeats in DMI patients results in the
decrease or absence of MBNLI at its endogenous RNA binding sites. These endogenous
targets are hypothesized to be pre-mRNA transcripts of which MBNLI regulates the
alternative splicing. One such target is cTNT, where it has been shown to bind upstream
of and promote the exclusion of exon 5 (21, 35). The binding site is within a 32
nucleotide region that folds into a stem-loop, similar to a short CUG repeat stem-loop.
The cTNT stem-loop contains several C-G and U-G base pairs and two pyrimidine-
pyrimidine mismatches, but lacks adenosines. Strengthening the cTNT stem by adding
two Watson-Crick base pairs or weakening the stem by mutating 4 guanosines, decreased
binding by MBNLI in vitro (35). This indicates that MBNL prefers weaker stems over
stronger, purely Watson-Crick stems. A potential binding site motif for MBNLI of 5'-
YGCU(U/G)Y-3' was postulated by Ho et aI., which is different than the 5'-CHHG-3'
motif put forth by Kino et aI. (19, 21). The 5'-YGCU(U/G)Y-3' motif was identified by
looking at 4 potential binding sites in cTNT introns, 2 in a human cTNT intron and 2 in a
chicken cTNT intron. The 5' -CHHG-3' motif was identified by a yeast 3 hybrid assay
that used various RNA 3-mer and 4-mer repeats as bait. It is possible that MBNLl's
binding site is degenerate and that a combination or portions of both motifs are correct. It
is also possible that MBNLI recognizes different binding sites in endogenous targets than
it does in CUG or CCUG repeats. Evidence for this comes from the binding affinity for
the endogenous cTNT binding site being 5-10 fold higher affinity than the affinity for
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CUG repeats in vitro. More information about MBNL1's endogenous binding sites
will help to determine the correct binding motif.
SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT
MBNL1 and Mbl regulate alternative splicing, however only a handful of pre-
mRNA targets have been identified. Within those targets, only one MBNL1 and no Mbl
binding sites have been recognized. The understanding of both DM1 symptoms and
muscleblind's functions in regulating splicing would be helped greatly if binding sites
were identified. This would allow for the creation of a complete list of muscleblind
targets and binding locations within each target. Systematic evolution of ligands by
exponential enrichment (SELEX) is a technique used in Chapter II and III to discover
RNA sequence elements and structural elements important for binding by Mbl and
MBNLl.
SELEX was established in 1990 as a technique to identify high affinity and/or
high specificity RNA aptamers (53, 54). SELEX applications cover a broad range, the
most common include identification of binding site motifs and selection for more
efficient or specific ribozymes (55). Examples include identification of RNA aptamers
that bind specifically to organic dyes, cleave single stranded DNA substrates more
efficiently, bind secondary structures with high affinity, and bind specifically to a protein
and block protease activity (53,54,56,57). SELEX has even aided in understanding
what sequence and structural element the HIV REV protein binds in the HIV RNA
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genome (58). With this information, drugs can be designed to disrupt the REVIHIV
genome complex.
SELEX can be performed with many permutations in technique; however, the
general scheme includes the design of a large starting pool of randomized DNA. The
initial DNA pool is then transcribed to create a large random pool of RNA. The protein
or target is then immobilized on beads or a surface. The pool of RNA is incubated with
the target to allow binding to occur. Washes are performed to remove the RNA that is
not bound. The bound RNA is harvested by chemical or heat denaturation of the target to
release the RNA. The RNA is then reverse-transcribed and PCR is performed to create
DNA. The DNA is then transcribed into a new pool of RNA termed round one. This
round one pool of RNA is enriched in RNA molecules that bind the target. This cycle
continues until enrichment is no longer taking place, anywhere from one cycle to tens of
cycles are performed (Figure 3).
SELEX is highly variable and can be suited to many different RNA-target
combinations. Each step of the SELEX process can be catered to the identification of
particular aptamers. The template usually includes two constant regions that playa dual
role; they serve as priming sites for the RT-PCR step and as an RNA polymerase T7
binding site. Usually the size of the constant regions are minimized to limit interaction of
the target to areas other than the random region. The random region can vary in length
according to the target, if a smaller binding site or a smaller active site is required, then
the region may be around 10 to 40 residues. However, if one is looking for a larger
binding site, one may use up to 100 random residues or more. A highly diverse initial
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pool is key to ensure that the best aptamers are available. Commonly 1014 - 1015
unique RNA molecules are used in the first round of SELEX (59).
iterative cycle
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1014_1015
RNAs
RT-PCR and ,..nscribe
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to amplify RNA ~ \
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-----. tl. target (protein)
bind RNA pool to protein~ ...~bir
~ I .- rd RNA to immobilized target
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elute bound RNA
.. protein bound to bead
iii! RNA aptamer
Figure 3. Sytematic evolution of ligands by exponential enrichment (SELEX).
A random pool of RNA aptamers composed of two, flanking constant regions and
a randomized region is bound to an immobilized target. The immobilized target
and pool of RNA are incubated. The unbound RNA is removed and the bound
RNA aptamers are eluted. The RNA aptamers are reverse transcribed and PCR is
performed to amplify a pool of DNA. The DNA is transcribed to create an
enriched pool of RNA aptamers. The process is repeated until enrichment of RNA
aptamers is no longer observed.
The binding conditions should take into account the interaction between the RNA
aptamer and the target so that some selectivity can take place. It is important to have a
portion of the RNA bind, but not all of it. The stringency of the binding conditions can
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be increased as the rounds increase to ensure removal of low affinity aptamers.
Stringency can be changed by increasing the ratio of RNA to protein or increasing the
concentration of salt and/or a nonspecific inhibitor. This allows the target to sample large
numbers of RNA molecules and bind only the highest affinity aptamers. To monitor the
effectiveness of each round, assays are performed to determine how many rounds are
required. In the case of identifying RNAs that bind with high affinity to a protein of
interest, gel mobility shift assays are performed to check the change in binding affinity
over the rounds. Once there is no longer an increase in binding affinity, the first round
where the highest affinity is achieved is cloned and sequenced. It is important to not
over-select as the aptamer diversity or biological relevance may be compromised.
A variation on the common SELEX technique is doped SELEX. Instead of a
completely randomized region for the target to bind, the "randomized" region is doped
with varying amounts of a known, wild type binding site. The doping can be as extensive
as the majority of wild type positions being randomized (partially or fully) or as low as
only a few positions being partially randomized with the rest remaining wild type. This
technique is useful if a large region of RNA is known to have a protein binding site in it,
but the exact nucleotides it interacts with or the nucleotides required to set up a specific
structure are unknown. In the case of the HIV-l REV protein, which binds the HIV-l
genome, the binding region had been narrowed down to 66 nucleotides. A doped SELEX
narrowed down REV's binding specificity to an essential G-G bulge in a stem-bulge-stem
region (58). Doped SELEX is a powerful tool to identify specific structural or sequence
elements that are required for binding by a protein of interest.
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DISSERTAnON OVERVIEW
The previous sections have outlined the role that muscleblind proteins play in
both the disease mechanism of myotonic dystrophy type 1 and as regulators of alternative
splicing. Muscleblind regulates the splicing of several important tissue and
developmentally specific transcripts. When MBNLI becomes sequestered to aberrant
CUG repeats in DMI patients, MBNLI can no longer regulate these transcripts. This
results in expression or degradation of inappropriately spliced mRNA. The lack of
appropriately spliced products leads to symptoms of DMl, such as myotonia and insulin
resistance. However, many more symptoms are unaccounted for and only a handful of
MBNLl-regulated pre-mRNAs have been identified. In addition, only one endogenous
binding site has been identified for MBNLl.
The Drosophila DMI model has already proven helpful in understanding the role
of muscleblind in development and CUG/Mbl foci formation. There is only one
muscleblind gene in Drosophila, not three like in humans, and Mbl only contains two
zinc fingers, not four like humans. This simplicity makes Mbl an ideal protein to
characterize muscleblind's RNA binding specificity. In Chapter II, binding of Mbl to
structured CUG repeat RNA is analyzed. In addition, SELEX is performed in order to
determine key sequence and structural elements required for binding by Mbl. The results
of these studies indicate that Mbl is a highly specific RNA binding protein that prefers
both single stranded and double stranded regions of RNA as well as guanosines. Chapter
II is currently published in the Biochemistry (Vol. 47, pp. 7284-7294, 2008) and titled
"RNA Binding Specificity of Drosophila Muscleblind". I am the first author and
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performed the majority of the experimental work with the help of Devika P. Gates.
Rodger B. Voelker, the third author, performed the bioinformatics. My advisor, J.
Andrew Berglund, is last author and helped in authorship, editing and experimental
design.
The identification of additional MBNLI binding sites in endogenous targets is
useful for linking mis-splicing events to DMI and DM2 symptoms and characterizing
MBNLl's mode of alternative splicing regulation. Little is known about the mechanisms
by which tissue specific alternative splicing regulators work. Even less is known about
splicing regulators that bind structured RNA, like MBNLI. Chapter III discusses the
results from a doped SELEX performed on the only known MBNLI binding site in cTNT
pre-mRNA. This doped SELEX aids in understanding MBNLI 's RNA sequence
preferences. Chapter III work is currently being prepared as a manuscript with the help
of Devika P. Gates, Rodger B. Voelker and J. Andrew Berglund.
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CHAPTER II
RNA BINDING SPECIFICITY OF DROSOPHILA MUSCLEBLIND
Reproduced with permission from Goers, E. S., Voelker, R. B., Gates, D. P., and
Berglund, J. A. (2008) RNA binding specificity of Drosophila muscleblind, Biochemistry
47, 7284-7294.
INTRODUCTION
Drosophila muscleblind (Mbl) is an RNA binding protein important in
differentiation and development. Mbl is known to have roles in photoreceptor
differentiation as well as terminal muscle differentiation (l, 2). In addition to roles in
differentiation, Mbl is necessary for early development as Mbl null flies die at late
embryo stages or early larval stages (2). Mbl has recently been shown to regulate the
alternative splicing of two genes involved in the cytoskeleton, a-actinin and tun (3, 4).
The human orthologues ofMbl are the muscleblind-like proteins (MBNLI-3) and these
proteins also regulate alternative splicing of transcripts important in development (5, 6).
Alternative splicing of the Mbl transcript leads to the production of at least four different
Mbl protein isoforms ranging in size from 84 to 316 amino acids. Three Mbl isoforms
presumably confer RNA binding through two CX7CX6CX3H zinc fingers; the shortest
Mbl isoform contains only one zinc finger.
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The MBNL proteins have been shown to play an important role in myotonic
dystrophy (OM) in humans. There are two subtypes of DM, both involving repeat
expansions that result in toxic RNAs. Myotonic dystrophy type 1 (DMl) is caused by an
expansion of CTG repeats in the 3' -UTR of the DMPK gene (7-9), while myotonic
dystrophy type 2 (DM2) is caused by an expansion of ccrG repeats in the first intron of
the ZNF9 gene (10). These two types of expansions appear to function through a
common disease mechanism: upon transcription, both the CUG and CCUG repeats fold
into double-stranded stem-loops with the helices adopting a primarily A-form structure
(11-13). MBNL proteins bind these stem-loop structures leading to the sequestration of
these important splicing factors in nuclear foci (14-16). MBNL sequestration results in
mis-splicing of various transcripts, several of which have been linked to symptoms
observed in DM patients (reviewed in refs 5 and 6).
Approximately 20 different human pre-mRNAs have been shown to be mis-
spliced in DM (6). The most well-characterized example of mis-splicing in DM is the
cardiac troponin T (cTNT) pre-mRNA in which MBNLI has been shown to promote
exclusion of an alternatively spliced exon (17). cTNT is developmentally regulated, and
the presence or absence of this exon determines if the expressed protein is the fetal or
adult isoform, respectively (18-21). Incorrect cTNT splicing in DMI patients may be
linked to cardiac abnormalities, one of the symptoms of DMI (5). The binding site for
MBNLI in the cTNT pre-mRNA has been mapped to a region upstream of the skipped
exon (17). Recently, we have shown that this section of cTNT RNA folds into a stem-
loop with mismatches and adopts a structure similar to the CUG repeat RNA which
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contains U-U mismatches (22). Yuan and colleagues have also shown that MBNL1
binds a stem-loop containing a pyrimidine-pyrimidine mismatch in an intron near the
Tnnt3 fetal exon (23), suggesting MBNL recognizes structured RNA elements in its pre-
mRNA targets.
Drosophila has been used as a model to investigate several aspects of DM1
pathology. Drosophila overexpressing 162 CUG repeats have nuclear foci that contain
localized Mbl and CUG repeats but do not display any abnormal phenotypes (24).
Longer, interrupted CUG repeats (480 repeats) result in nuclear foci and cause the flies to
have muscle, eye, and other degeneration phenotypes, consistent with the Mbl null flies
(l, 25). Overexpression of human MBNL1 can rescue these mutant phenotypes (26),
indicating MBNL1 and Mbl are functionally conserved. Since Drosophila has one mbl
gene with four protein isoforms (while humans have three muscleblind-like genes, each
with multiple isoforms) experimental design and data analysis can be simplified when
using Drosophila as a model system. Characterization of the RNA binding properties of
Drosophila Mbl will lead to a better understanding of its role in alternative splicing and
the role of MBNL in DM. In this study we show that recombinant Mbl (amino acids 1-
105) is a highly specific RNA binding protein with a strong preference for structured
RNA containing specifically placed guanosines.
---------------_._-_._.- ._..
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MATERIALS AND METHODS
Protein Construct Design and Protein Purification
Mbl eDNA (amino acids 1-105) was amplified by PCR from the Drosophila
eDNA library DGC release 2 using primers: 5'-
GCGAATTCGCCAACGTTGTCAATATGAACAGC-3' and 5'-
ATAGTTATGCGGCCGCTCAGCCCATCTGTTGCATCAGTGC-3' and restriction
digested with EcoRI and Not!. The PCR product was ligated into pGEX6P-l
(Amersham) to create the Mbl (1-105) construct, which has a N-terminal glutathione S-
transferase (GST) tag. This construct was expressed in Escherichia coli Rosetta cells and
grown in LB medium with 50 mM ZnCl2, 50 mg/mL Amp, 25 mg/mL chloramphenicol,
and 2% glucose at 37°C. Cells were induced at an OD6oo of 0.5-1.0 with 0.4 mM IPTG at
30°C for 3 h. Cells were then pelleted and stored at -80°C. The pellet was dissolved in
lysis buffer (500 mM NaCl, 25 mM Tris pH 8.0, 10 mM BME and 5% glycerol),
sonicated, and centrifuged at 31,000 x g for 15 min. The supernatant was bound to
glutathione-agarose beads for 30 min to Ih at 4°C. The protein was eluted with 10 mM
reduced glutathione, diluted to 60 mM NaCI, and run over a Source 30Q anion-exchange
column (Amersham). Protein impurities bound to the column, but Mbl did not; therefore,
flow-through was collected, concentrated, and dialyzed into protein storage buffer (50%
glycerol, 25 mM Tris pH 7.5, 5 mM BME, 0.1 % triton x-lOO and 500 mM NaCl)
overnight at 4°C. The presence of the GST tag does not appear to alter RNA binding
because removing GST did not alter the RNA binding of Mbl (data not shown).
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Transcription and Kinase Reactions
RNA oligonucleotides were transcribed with T7 RNA polymerase and (a_32p)
CTP from linearized plasmids, PCR products or fully complementary DNA oligos. The
transcription reaction mixtures were incubated at 37°C for 3 h or 25°C overnight. RNAs
were kinased using T4 polynucleotide kinase and [y_32p] ATP. Both transcribed and
kinased RNAs were gel purified with 8% denaturing polyacrylamide gels.
Gel Mobility Shift Assay
Radiolabeled RNA was heated at 95°C for 3 min and then placed directly on ice
for 10 min in binding buffer (20 mM Tris pH 7.5,5 mM MgCl2 and 100 mM NaCl).
RNA was equilibrated to 25°C for 5 min. Heparin (final concentration of 0.5 mg/mL) and
loading dye were added to the RNA. Protein was serially diluted into protein storage
buffer on ice and aliquoted into 2 mL per binding reaction mixture at 25°C. RNA in
binding buffer (8 mL) was added to the aliquoted protein and allowed to bind for 15-30
min at 25°C. The RNA concentration was equal to or less than the dissociation constant
(Kd) value for each reaction. RNA-protein complexes (2 ml per binding reaction
mixture) were resolved with a native polyacrylamide gel (6% 37.5: 1
acrylamide/bisacrylamide mixture and 0.5X TB) run at 4°C for 30 min at ~150 V. The
gels were dried and exposed to a phosphoimager screen (Molecular Dynamics) overnight
at 25°C. ~ values were determined on the basis of quantitation of the bound and
unbound RNA fractions using ImagQuant (Molecular Dynamics). Kd values were
calculated as described by Warf and Berglund (22).
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SELEX
The template for the SELEX (systematic evolution of ligands by exponential
enrichment) (27) experiment was the 80-mer DNA oligonucleotide 5'-
GGGAATGGATCCACATCTACGAATTCN3~TCACTGCAGACTTGACGAAGCTT-
Table 1: Concentration of RNA and
Protein used in SELEX
round RNA (flM) Protein (flM)
1 20 5
2 1.2 0.12
3 4.3 0.43
4 2.4 0.24
5 5.6 0.56
6 0.56 0.056
3'. The forward primer for SELEX was 5'-
GATAATACGACTCACTATAGGGAATGGATCCACATCTACGA-3' and the reverse
primer was 5'-AAGCTTCGTCAAGTCTGCAGTGAA-3'. The initial PCRs were
amplified by eight rounds of PCR and calculated to a concentration of lxlOl4 molecules.
The transcription reactions were conducted under the following conditions: 100-2000 ng
of template, 40 mM Tris pH7.9, 26 mM MgClz, 2 mM spermidine, 10 mM NaCl,
nucleotides (5 mM each), 0.1 pg of yeast pyrophosphatase/l00 pL, ",2 mg/mL T7
polymerase, and 40 mM DTT . The transcription reactions were performed with small
amounts of [a_3Zp] CTP for monitoring purposes. After transcription, reactions mixtures
were treated with DNase for 1 hr at 37°C, gel purified, ethanol precipitated and run over a
Bio-Spin-6 size exclusion column (Bio-Rad). For each round, the appropriate
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concentration of Mbl (1-105) was bound to 20 mL of glutathione-agarose beads at 4°C
for 15 min, then washed three times with 200 mL of SELEX binding buffer (160 mM
NaCl, 25 mM Tris pH 7.5,5 mM MgClz, 0.002% triton x-lOO and 1 mM BME added the
day of use). This amount of beads should be enough to completely bind all of the added
Mbl. All washes were conducted in a similar manner. The RNA was heated in SELEX
binding buffer at 95°C for 3 min and placed immediately on ice for 10 min. tRNA (0.1
mg/mL) was added, as a nonspecific inhibitor, to the RNA (in all rounds except round 3).
Negative selection was carried out on glutathione-agarose beads prior to binding to Mbl-
bound beads by prebinding the RNA to the glutathione-agarose beads. The Mbl-bound
beads were incubated with the RNA at 25°C for 20 min. The beads were washed three
times in 200 mL of SELEX binding buffer and RNA was released and collected from the
beads by a phenol/chloroform extraction and subsequent ethanol precipitation. The
collected RNA was reverse transcribed using AMY reverse transcriptase, AMY buffer,
8.8 JIM reverse primer, and two-thirds of the RNA isolated after the round for 1 hr at
42°C. After the reverse transcription was complete, the DNA was amplified by 11 PCR
cycles. The DNA was transcribed and the SELEX cycle repeated six times with the
concentration of RNA and Mbl varying according to Table 1. After the rounds were
completed, individual clones were isolated by Tapa cloning and then sequenced.
Structure Probing and Footprinting
RNA was transcribed, and the terminal triphosphate was removed using shrimp
alkaline phosphatase (USB) and then kinased using T4 polynucleotide kinase (NEB) and
[g _3Zp]ATP to 5' -end label the RNA. The RNA was gel purified and
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ethanol precipitated. Purified RNA was incubated with either RNase Tl, RNase VI, or
RNase 1 or under alkaline hydrolysis conditions (Ambion) in footprinting buffer and
protein storage buffer (20% glycerol, 0.04% triton X-lOO, 2 mM BME, 20 mM Tris pH
7.5,200 mM NaCl, 100 mM KCl, 0.5 mg/mL tRNA and 10 mM MgCI2) to a final
volume of 10 JlL for 3 min. Reactions were quenched with phenol-chloroform and
extracted. In the reaction mixtures containing Mbl, Mbl was added in protein buffer to a
final concentration of 4 or 12 !!M and incubated with RNA for 10 min at 25°C before
RNases were added. After the phenol extraction, the RNA was ethanol precipitated and
cleavage products were resolved with a denaturing 15% polyacrylamide gel for ",2 h at 35
W. The gel was dried and exposed to a phosphoimager screen overnight at 25°C.
Determination ofn-mer Bias in the SELEX Sequences
SELEX was initiated with a population of RNAs containing a uniformly random
sequence; however, the random sequence was flanked by two constant regions that are
necessary for amplification. It is possible that the nonrandom sequences can inadvertently
influence the selection process (e.g., by directly acting as a binding site or by interacting
with the nonrandom region to form secondary structures that influence binding).
Therefore, we developed a method for calculating enrichment that attempts to account for
the constant regions. To calculate the degree to which n-mers were enriched during the
SELEX, we first performed a sliding-window count of all n-mers (3 to 5 nt) within the
non-redundant sample of 25 selected sequences. This count included the entire constant
and random regions. To calculate the maximum likelihood probabilities for expected
occurrences we also performed a similar sliding-window count on a set of 500,000
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computer generated sequences containing a uniformly random 30 nt region flanked by
the same constant regions used in the experiment. For both of these data sets the counts
were transformed to probabilities and the enrichment was determined according to the
binomial confidence interval method previously described (28).
RESULTS
A Minimal Mhl Protein Binds Specifically to Expanded CUG and Short CUG Repeats
To characterize the RNA binding specificity and affinity of Mbl, we have
designed a minimal protein - RNA system. Initially we began our RNA binding studies
with a full-length version of Mbl (amino acids 1-243), isoform C of the four different
alternative splice forms of Mbl. However, due to its low level of solubility and
instability, Mbl (1-243) proved difficult for use in binding studies. The first 100 amino
acids are highly conserved and contain the zinc finger domains. We therefore truncated
Mbl by removing the C-terminus and fused the N-terminal 105 amino acids to an N-
terminal GST tag, creating a more stable protein. This construct will be referred to as
Mbl and all experiments were performed with Mbl unless otherwise indicated.
Mbl bound to fifty four CUG repeats (CUG54) with a Kd of 500 nM (Figure 1A)
while a minimal RNA containing only four CUG repeats with a UUCG cap (CUG4)
bound Mbl with a Kd of 430 nM. (Figure 1A). The UUCG cap is an ultra-stable loop that
forces stems to form and maintain stability (29). Normally 10 or more CUG repeats are
necessary for duplex formation and human MBNL1 binding (16). This minimal (CUG)4
RNA facilitates the dissection of the RNA binding specificity of Mbl by replacing
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Figure 1. Mbl binds CUG repeats with a high degree of specificity. (A) The four
gels are gel mobility shift assays with the name of the RNA above each gel, the
structure of the RNA below each gel, and increasing concentrations of Mbl along the
top. The GU mutant gel contains (CUG)4 with the U-U mismatches replaced with G-
U base pairs. The GUC mutant has reversed 5' to 3' orientation compared to (CUG)4'
The nucleotides mutated relative to (CUG)4 are shown in bold. The Mbl
concentrations in panel A are 0.15 JlM, 0.45 JlM, 1.4 JlM, 4.1 JlM, and 12 JlM. The Kd
values refer to the RNA oligonucleotides shown in the gel above. (B) The secondary
structures of 10 other CUG mutant RNA oligonucleotides that were tested for binding
by Mbl. Only the C-U and C-C mutants (l and 2) bound to Mbl, while the other eight
RNA oligonucleotides (numbers 3-10, shaded in gray) showed no binding with up to
12 JlM Mbl. The nucleotides mutated relative to (CUG)4 are shown in bold. The Kd
values were determined on the basis of a minimum of three independent gel mobility
shift experiments.
the U-U mismatches and/or C-G base pairs with other bases. Using this strategy we
measured the binding affinities of twelve (CUG)4 mutants. We found that when the U-U
mismatches were replaced with C-U or C-C mismatches, Mbl bound with only a 2-fold
decrease in affinity compared to (CUG)4 (Figure IB). However, mutating the U-U
mismatches to G-U wobble base pairs or purine-purine mismatches such as A-G, A-A or
G-G abolished binding (Figure IB). Replacing the U-U mismatches with Watson-Crick
base pairs also disrupted binding by Mbl (RNA #7 and #8, Figure IB). Furthermore,
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changes to the C-G and G-C Watson-Crick base pairs including reversing the
orientation of the RNA (5' -GUC-3 ') and making one strand all pyrimidines and the other
all purines eliminated binding by Mbl (Figure IB). Finally, an RNA with different
Watson-Crick base pairs at all of the positions didn't bind Mbl (RNA #10, Figure IB).
These results indicate that all of the positions of the CUG helix are important for binding,
and that the pyrimidine-pyrimidine mismatch is essential for binding.
Identification ofRNA Sequences That Bind with High Affinity to MhZ
SELEX was performed using Mbl and a random pool of 1014 RNA
oligonucleotides. Each RNA consisted of a 3D-nucleotide randomized region flanked by
shorter constant regions, creating an 80-nucleotide RNA. Twenty-five unique RNA
sequences were identified (five sequences were found multiple times) after six rounds of
SELEX. The sequences were classified into three groups according to the presence of
enriched motifs, binding affinities to Mbl and predicted secondary structures (Table 2 and
Figure 2).
An n-mer analysis comparing the expected occurrences in a sample of uniformly
random RNA sequences to the 25 SELEX sequences identified several highly enriched n-
mers (Table 2). The n-mers were found predominately in groups I and II and rarely in
group III with AGUCU identified as the most highly enriched 5-mer. Most of the high
scoring n-mers were located within two main regions of the SELEX sequences; UGUG,
GUGCG and CGGUA were 5' of the AGUCU sequence in Group I while AGUC
AGroup I
5' constant region random regian 3' constant region Mbl binding?
10 GGGAATGGATCCACATCTACGAATTCGGCTCGTIGGTGCCATCcmcGMGli!'iIfircACTGCAGACTTGACGMGOn +
14 GGGAATGGATCCACATCTACGAATTCACTGTAGATGATGGATGTGCGGTAGptmBlrrCACTGCAGACTTGACGAAGCn
20 GGGAATGGATCCACATCTACGAATTCACCGTAGArGATGGATGTGCGGTAGIl!!i7i1TTCACTGCAGACTTGACGAAGCn +
::~~~~~~~~~~~~~~~~~~r;::r~;:~~6G;g;GGtl£;ggG;::=.;~:g;~~:~:g;;:g~::~g~
48 GGGAATGGATCCACATCTACGAATTCGTGCGTAGGIGTGGTIGTGCGGTAGrmTflTTCACTGCAGACTTGACGAAGCn
5 GGGAATGGATCCACATCTACGAATTCTAGCTGTCGTAMTGIGGAGCGGTAAmmJ TCACTGCAGACTTGACGAAGCn
45 GGGAATGGATCCACATCTACGAATTCGTITCGACGATGTGGATGTGCGGTAGlj!'iJ'A1rcACTGCAGACTTGACGAAGCTT +
44 GGGAATGGATCCACATCTACGAATACATCGAAQGTATGGATGCGCGGTAArmB'JAncACTGCAGACTTGACGMGOn
23 GGGAAGGATCCACATCTACGAATTCGAGGJAGCGCTGTGGATGTGCGGTAcfh!!iAi TCACTGCAGACTTGACGAAGCTI +
3S GGGAATGGATCCACATCTACGAATICTCGAGTGTTAGGTGTGGMGCGGTAGmm'I TCACTGCAGACTIGACGAAGCTT
36
37 TTGAATGGATCCACATCTACGAATTCAmtiDgAGCUCrmCATGWMATAGCTICACTOCAGACTIGACOAAGCTI
Group II 46 GGGAATGGATCCACATCTACGAATTCAQi5li1sGGCCTCTITAGTGCMTMATGCTTCACTGCAGACTIGACGAAGCTI
38 GGGAATGGATCCACATCTACGAATTCArmmnAGCCTCmAGTGCMTAMTGCTICACTGCAGACTIGACGAAGCTT
50 GGGAATGGATCCACATCTACGAATICAmmGAGCCTCTGGACG~TICACTGCAGACTTGACGAAGCTT+
19 GGGAATGGATCCACATCTACGAATTCCCTCGTCATGTTCATGCAACGCGTGCGCGATTCACTGCAGACTIGACGAAGCTI +/~
26GGGAATGGATCCACATCTACGAATTCTGAGGTTATATGCTGTCATGCITGCGGGnnCACTOCAGACTTGACGAAOCTI
16 GGGAATGGATCCACATCTACGAATICTTCGCGAATGACCAMGAACTC',AGGTACGTTTCACTGCAGACTTGACGAAGCT
22 GGGAATGGATCCACATCTACGAATTCTCGAGGATAUCCTGCTTGGTCAGTTCTGTTTCACTGCAGACTIGACGAAGCTI
Group III 29 GGGAATGGATCCACATCTACGAATTCGTCCGAGTCATAACGCAGGCGTAMCGCGATTCACTGCAGACTIGACGAAGCTI
34 GGGAATGGATCCACATCTACGAATTCGCTCMGTTGCTTGTGCGTGMCAWCGCATICACTGCAGACTIGACGAAGCTI
3<J GGGAATGGATCCACATCTACGAATICCCTCGTCAAICAIGCACTCGTGGCGCGAGATTCACTGCAGACTIACGAAGCTT
15 GGGAAIGGAICCACATCIACGAATTCGCTCMGTIGCUGTGCGIGAACATGCGCGTICACTGCAGACTTGACGAAGCTI
36 GGGAAIGGAICCACAICIACGAATTCTGCTAGAATCTAAQGAGGAAGGGTGTATICTTCACTGCAGACTIGACGAAGCTT
B #50
Figure 2. High-affinity RNA ligands for Mbl identified by SELEX. (A) The 25
SELEX RNA sequences were separated into three groups on the basis of whether they
contained 5'-AGUCU-3' and then further categorized by the location of the 5'-
AGUCU-3' sequence within the random region. The location of the 5'-AGUCU-3'
sequence dictated the fold of the RNA, which also contributed to the grouping. Group
I RNA sequences contain 5'-AGUCU-3' (black boxes) near the 3'-end of the random
region while Group II RNA sequences contain 5' -AGUCU-3' near the 5' -end of the
random region. Both Group I and II RNA sequences bound Mbl with Kd values of
;5;50 nM. The + indicates a Kd value of <50 nM, the +/- indicates a Kd value of roo.; 300
nM and the - indicates a Kd value of >300 nM. Group III RNA sequences did not
contain 5' -AGUCU-3', did not fold into a common structure, and had Kd values of
>300 nM. (B) The 5'-AGUCU-3' sequences of both group I and II (black boxes) form
a double-stranded region with 5'-AGACU-3' found in the 3'-constant region, giving
rise to characteristic, predicted secondary structures within each group. RNA 20
represents the common fold of group I RNA sequences, and RNA 50 represents the
common fold of group II RNA sequences. The hatch marks indicate the divisions
between the constant regions and the randomized region.
--------------------------------
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was found within the AGUCU sequence. Almost all group I SELEX sequences fold
into a common structure (similar to RNA 20, figure 2B) of two stems connected by a
linker of one to three nucleotides. The location within the predicted secondary structures
for the n-mers found 5' of AGUCU was generally in the linker between stem 1 and stem
2 or the base of stem 2. It is possible that these sequences were selected during SELEX
to promote specific secondary structures.
Group I and II RNA sequences bound Mbl with high affinity (Kd values ranged
from 0.050 to 1.0 nM, Figure 3), while group III RNA sequences bound Mbl weakly or
not at all (Figure 3). Group I and II RNAs both contained the highly enriched sequence,
5' -AGUCU-3', in the random region that base pairs to a region in the 3' -constant region.
In group I, this consensus sequence was located at the 3'-terminus of the randomized
region, while in group II the sequence was located at the 5' -terminus of the randomized
region (Figure 2A). Occasionally, the consensus sequence spanned the junction of the
randomized region and the 3' -constant region (for the group I sequences). For group I
sequences, the reverse complement of the consensus sequence (5' -AGUCU-3') was
found six to nine nucleotides downstream from the consensus sequence. For sequences
in Group II, the reverse complement of the consensus sequence was found 32 nucleotides
downstream in the constant region. Regardless of the distance between the consensus
sequence and its reverse complement, the minimal free energy structures (according to
mfold) predicted that the 5'-AGUCU-3'/5'-AGACU-3' sequences were paired. The
double-stranded consensus region (5' -AGUCU-3'IS' -AGACU-3') was found in all
SELEX RNA sequences that Mbl bound tightly and corresponded to regions of common
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structural aspects across Group I and II (Figure 3A,B), suggesting this motif is a core
component for Mbl binding.
The Secondary Structure and MhZ Binding Site on a SELEX Group I RNA
Structure probing and footprinting were performed to determine if the secondary
structure of the group I RNA sequences (predicted by mfold 30) was correct and to
identify the Mbl binding site. RNA 20 was chosen for this characterization because, of
the group I RNAs tested, it bound the tightest (Figures 2A and 3A). The structure
probing with RNase Tl, RNase VI and RNase 1 revealed that the mfold structure
prediction was consistent with the experimentally-determined structure (compare Figures
2B and 4C). The results of the RNase Tl cleavage, which is specific for single-stranded
guanosines, are shown in panels A and B of Figure 4 (lane 3). Cleavage sites were
identified at Gl, G2, G8, G21, G39, G40, G43, G45, G47, G48, G51, G53, G63, G66,
G71, G74, and G77. Lane 6 (Figure 4A,B) shows the results of RNase VI, which
preferentially cleaves in double-stranded regions or regions adjacent to double-stranded
RNA. The cleavages by RNase VI were seen in stem lA (nucleotides 11-22), stem IB
(nucleotides 31, 36, 39,40, and 42), the base of stem 2A (nucleotides 46 and 47), and
stems 2A and 2B (nucleotides between positions 53 and 78 display cleavage; however,
the resolution of the gel does not allow discrete nucleotides to be identified). Different
levels of cleavage by RNase VI in stem lA and stem IB were observed; it is possible
that the tertiary structure of RNA 20 allows some regions of stem 1 to be more accessible
to cleavage than other regions.
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The addition of Mbl significantly altered the cleavage pattern at three positions.
All three nucleotides are guanosines, which were strongly protected from RNase Tl,
RNase VI, and RNase 1 activity. G53 was protected from RNase VI by Mbl at both
Table 2: Highly Enriched n -mers Found in SELEX Sequences
n -mer observeda expectedb P value
AGUCU 15 0.740438 1.03E-61
GUGCG 11 0.625438 2.54E-39
CGGUA 10 0.717688 5.82E-28
UGUG 17 2.63369 7.81E-19
UGCG 16 2.61488 1.06E-16
AGUC 16 2.65144 2.07E-16
GUG 32 10.9052 1.33E-1O
GCG 29 10.9132 3.68E-08
GUC 23 10.9851 2.56E-04
a Observed is the total occurrences of the n -mer within the sample
of 25 SELEX sequences.
b Expected is the number of occurrences according to the maximum
likelihood estimate in a random pool of RNA of the same size as the
25 SELEX sequences.
concentrations of Mbl, 4 JlM and 12 JlM (Figure 4B, lanes 7 and 8). G63 was protected
from RNase Tl cleavage at both Mbl concentrations as well. G77 was protected from
RNase Tl cleavage but only slightly protected from RNase V 1 and RNase 1 by Mbl. This
protection indicates Mbl binds RNA 20 within stem-loop 2 and the 3' -tail (Figure 4C).
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Figure 3. RNA sequences from Group I and II bind Mbl with high affinity. (A)
Gel mobility shift assays with RNAs 20 and 45 from Group I are shown. A
schematic representation of their predicted secondary structures is shown to the right
of the gels. The box represents the random region, and the black portion represents
the 5' -AGUCU-3' sequence and the gray section the 5' -AGACU-3' sequence in the
3'-constant region. Mbl concentrations for the RNA 20 gel were 0.12 nM, 0.92 nM,
7.3 nM, 58 nM, and 470 nM. Mbl concentrations for the RNA 45 gel were 0.92 nM,
7.3 nM, 58 nM, 470 nM and 3600 nM. (B) Gel mobility shift assays with RNAs37
and 50 from Group II and a schematic representation of their predicted secondary
structures. Mbl concentrations for the RNA 37 gel were 0.014 nM, 0.12 nM, 0.92
nM, 7.3 nM and 58 nM. Mbl concentrations for the RNA 50 gel were 0.12 nM, 0.92
nM, 7.3 nM, 58 nM, and 470 nM. (C) RNAs 19 and 30 from Group III bind Mbl
with a Kd value >30 JlM. Mbl concentrations for RNA 19 and 30 gels were 0.0073
JlM, 0.058 JlM, 0.47 JlM, 3.6 JlM, and 30 JlM. ThtKd values were determined on
the basis of a minimum of three independent gel mobility shift experiments.
No protection was observed in stem 1 or the 5' -tail, which is consistent with the binding
information used to group the SELEX RNA sequences. G53 is in the 5' -AGUCU-3'
consensus motif, implying Mbl directly binds this particular guanosine in stem 2.
In the SELEX sequences, guanosines made up 33% of all bases while adenosine,
uridine, and cytosine made up 22, 27, and 18%, respectively, of the base composition of
the randomized region after six rounds of SELEX. These results suggest Mbl selected for
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guanosine-rich sequences and against cytosine-rich sequences while adenosines and
uridines were neutral. The selection against cytosines is surprising because Mbl and
MBNL bind eUG and eeUG sequences. The bias toward guanosines in the SELEX
sequences could be the result of selecting for structured, stable RNAs within a relatively
short randomized region due to the fact that guanosine can bind both cytosine and
uridine.
Truncation and Mutational Analysis Identifies Features ofSELEX RNA 20 That Are
Essential for Binding by Mbl
To determine a minimal binding site within SELEX RNA 20, binding studies
were conducted with the 5' - and 3' -halves of the RNA, dividing it between nucleotides
44 and 45 to maintain stem 1 (stem-loop 1 half) and stem 2 (stem-loop 2 half). The stem-
loop 2 half RNA contained an additional three guanosines at the 5' -end that was
necessary for transcription using T7 RNA polymerase. No binding was observed
forstem-loop 1 half RNA and weaker binding was observed for stem-loop 2 half RNA
('"1ODD-fold lower affinity than that of full length RNA 20) (Figure 5). This is consistent
with the Mbl footprinting to stem 2, but the significant loss of binding with just stem-loop
2 half compared to the full-length RNA indicates that at least a portion of stem-loop 1
half aids Mbl binding. Many of the highly enriched n-mers (Table 2) are located at the
base of stem 1 and the linker between stem 1 and stem 2 which were disrupted in the
stem-loop 1 half and stem-loop 2 half truncations. To identify the 5' -region that aids in
Mbl binding, we began deleting sections of the RNA and found that removing the
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majority of the eight nucleotide 5' -tail abolished Mbl binding, indicating that the 5'-
tail is required for binding (truncated 5' -tail, Figure 5). When a different RNA tail (six of
eight nucleotides in the 5' -tail were mutated) was added back, binding was partially
restored (Kd value of 140 nM for mutated 5' -tail·RNA compared to 0.23 nM for full-
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Figure 4. Secondary structure determination and identification of the Mbl
binding site on RNA 20. (A) Structure probing was performed on RNA 20 with
RNase Tl, VI, and RNase1 in the absence and presence of Mbl. Lane 1, free RNA,
shows some degradation that was considered as background cleavage. Alkaline
hydrolysis of RNA 20 was performed and run in lane 2. The concentration of Mbl
ranged from 4 to 12 !lM. The solid lines to the left of the gels indicate regions of
double-stranded RNA; dashed lines indicate regions of single-stranded RNA. The
numbers on the right of the gel correspond to residue number. (B) This is an
enlargement of the upper region of the gel shown in panel A. The white arrows
highlight protection of three guanosines by Mbl: G53, G63 and G77. (C) The
predicted secondary structure of RNA 20 from mfold with cleavages from the three
RNases (30). The three sizes of symbols indicate the intensity of the cleavage. Pins
with circles indicate RNAse Tl cleavages, T symbols indicate RNA VI cleavages and
triangles indicate RNAse 1 cleavages. The large, bolded guanosines indicate bases
protected by Mbl.
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length RNA 20, Figure 5), indicating that both the presence of the tail and its sequence
are important for Mbl binding.
Not surprisingly, deleting the six nucleotide 3'-tail abolished Mbl binding; one of
the guanosines that Mbl protected is within this region (Figure 5). To determine if the 5'-
and 3' -tails from the SELEX RNA 20 could generally enhance Mbl binding, we added
these tails to the (CUG)4 RNA and tested Mbl binding. Apparently, the tails are specific
to the SELEX RNA because the addition of the tails to the CUG repeats did not increase
the level of binding (data not shown). Next we reduced the length of stem 1, maintaining
the first four base pairs at the base of this stem and capping it with an ultrastable UUCG
sequence. Tight binding was maintained with no loss in affinity compared to the full-
length RNA 20 (shortened stem-loop 1 RNA, Figure 5). These binding studies indicate
that both the 3' and 5' tails are required for binding by Mbl, but that a minimal stem can
replace the extended stem 1 and maintain high-affinity binding. This suggests that the 5'-
tail, 3' -tail and stem 1 are important for the overall structure of the RNA and Mbl
binding.
To test the importance of the guanosines protected by Mbl, each was mutated
individually to adenosine. Each G to A mutation severely inhibited or eliminated Mbl
binding (Figure 6). G63 and G77 were in single-stranded regions that, when mutated, did
not affect the predicted structure. G53 and C68 were both mutated to form a new U-A
base pair to maintain the secondary structure of RNA 20; however mfold predicted a
change in structure. To determine if nucleotides near these guanosines are important for
binding, we introduced two additional single mutations. C59 was mutated from a cytosine
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to adenosine (data not shown) and A75 from an adenosine to a guanosine (Figure 6,
bottom right panel). Neither mutation affected Mbl binding. Our results suggest that
G53, G63, and G77 are positioned within the secondary structure in RNA 20 in such a
way as to facilitate high-affinity binding by Mbl.
Although the G53A mutation suggested this specific nucleotide was important for
Mbl binding, we wanted to determine if Mbl would still bind with high affinity if the 5'-
Cs1CACAC-3' / 5'-GUGUGG-3' to maintain the structure but not the sequence (2A/2B-
6, Figure 6). The affinity did not decrease compared to that of RNA 20, indicating that
the stem structure was selected for and not necessarily the sequence, although Mbl could
be contacting a different guanosine in this new sequence. The lack of obvious
pyrimidine-pyrimidine mismatches in SELEX RNA 20 was initially a puzzling result.
We hypothesized that loop 2 might contain one or more pyrimidine-pyrimidine
mismatches and function in a manner analogous to that of the mismatches found in the
MBNLI binding sites. To determine if the U57-C64 mismatch was important for Mbl
binding, U57 was mutated to a guanosine (U57G) to form a G-C base pair (G57-C64).
The level of binding to U57G was reduced 30-fold compared to that of RNA 20
suggesting that this mismatch plays a role in Mbl binding (Figure 6).
MhZ Recognizes an MBNLl Binding Site in the cTNT Pre-mRNA with High Affinity
MBNLI binds a stem-loop in the cTNT pre-mRNA and regulates the splicing of
the adjacent exon through this interaction (17, 22). To determine if Mbl binds this
45
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mutated 5' tail
Kd 140 ± 60 nM
290 ± 80 nM
truncated 3' tail
no binding
truncated 5' tail
"1 Pm: rr
no binding
shortened stem-loop 1
0.31 ± 0.24 nM
Figure 5. Mbl requires 5'- and 3'-single-stranded tails but not full-length stem-
loop 1 for high-affinity RNA binding. Various truncations and mutations of RNA
20 were bound to Mbl and analyzed using gel mobility shift assays. Stem-loop 1 half
and stem-loop 2 half RNAs were cleaved between residues 44 and 45 with three
guanosines added 5' to G45 in stem-loop 2 half RNA. Truncated 5' tail RNA was
deleted up to residue 6, and U6 was replaced with a guanosine. Six residues were
changed in mutated 5' tail RNA as indicated by the arrows. The residues were
mutated from 5'-G3AAUGG-3' to 5'-A3CUCCA-3'. Truncated 3'-tail RNA was
deleted up to residue 74. The shortened stem-loop 1 RNA was truncated up to the
12-39 base pair and replaced with a stable UUCG cap. Mbl concentrations were
0.0073 JlM, 0.059 JlM, 0.47 JlM, 3.8 JlM, and 30 JlM for stem-loop 1 half, stem-loop
2 half, truncated 5'-tail, mutated 5'-tail and truncated 3'-tail RNAs. Mbl
concentrations for shortened stem-loop 1 were 0.12 nM, 0.93 nM, 7.3 nM, 59 nM
and 470 nM. The secondary structures shown below each gel mark the location of
the truncation or mutation. The Kd values were determined on the basis of a
minimum of three independent gel mobility shift experiments.
MBNL1 pre-mRNA target, we performed binding studies with this cTNT RNA. A 50-
nucleotide region from within intron 4 of the cTNT pre-mRNA was found to form a
stem-loop that contains several pyrimidine-pyrimidine mismatches bordered by G-C and
2A/2B-6
Kd 0.28 ± 0.18 nM
U57G
6.9 ± 1.3 nM
G63A
oo.~
no binding
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Figure 6. Mbl binds specific structural elements and sequences. In 2A/2B-6
mutant RNA, six base pairs in stem 2 (containing the AGUCU consensus region)
were mutated to maintain the structure but change the sequence. In U57G mutant
RNA, a potential U-C pyrimidine-pyrimidine mismatch was mutated to a G-C base
pair. The three guanosines (G53, G63, and G77) that exhibited strong protection in
the footprinting assay were individually mutated to adenosines. The arrows indicate
the residue or group of residues that was mutated. A75G mutant RNA was tested for
binding to Mbl as a control. Mbl concentrations for U57G, G63A, G77A, and
G53A/C68U mutant gels were 0.0073 JlM, 0.059 JlM, .47 JlM, 3.8 JlM, and 30 JlM.
Mbl concentrations for 2A/2B-6 and A75G mutant gels were 0.12 nM, 0.92 nM, 7.3
nM, 59 nM, and 470 nM. The Kd values were determined on the basis of a minimum
of three independent gel mobility shift experiments.
G-U base pairs (Figure 7A). Mbl binds this RNA with a Kd value of 0.67 nM, an affinity
similar to that of the Mbl SELEX RNA sequences (Figure 7B). Mutating four of the
guanosines to pyrimidines eliminates binding at the Mbl concentrations that were tested
(Figure 7B). These mutations reduce the level of MBNLI binding by 100-fold (22),
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while Mbl appears to display even more specificity (>500-fold). This result shows that
Mbl is capable of recognizing human MBNLI sites and suggests Mbl may recognize
similar RNA motifs during splicing regulation in Drosophila.
DISCUSSION
This first characterization of the RNA binding properties of Mbl shows that the
protein is a very specific and high-affinity RNA binding protein. Mbl binds CUG repeats
as expected (Figure 1) on the basis of the findings that, like MBNLl, Mbl colpcalizes
with CUG repeats in Drosophila (24). The high specificity of Mbl for the CUG repeat
RNA is surprising. We previously found that MBNLI tolerated many different mutations
to the CUG repeats (22), while Mbl only tolerated replacement of the U-U mismatch with
other pyrimidine-pyrimidine mismatches (Figure 1). This indicates that Mbl is a more
specific RNA binding protein than MBNLI.
Using SELEX, we identified RNAs that bound Mbl with Kd values ranging from
the picomolar to the low nanomolar range. All of these RNAs contain the consensus
motif of 5' -AGUCU-3' (Figure 2). The footprinting studies suggest Mbl interacts
directly with the guanosine in this sequence, and mutating this nucleotide eliminated Mbl
binding (Figures 4 and 6); however, the importance of this sequence is partly or fully due
to the fact that it base pairs with a region (5' -AGACU-3') in the constant region. This
was demonstrated by changing the sequence of the stem 2 and finding that the affinity of
this RNA for Mbl was the same as that for RNA 20 (Figure 6). It is possible that Mbl
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Figure 7. Mbl binds a human MBNLI binding site in cTNT pre-mRNA with
high affinity and specificity. (A) Secondary structure of the cTNT RNA based on
structure probing by Warf and Berglund (22). The arrows indicate the four
guanosine to pyrimidine mutations (mutant cTNT) that abolish the stem structure.
(B) Gel mobility shift assays of the 50 nucleotide region of cTNT RNA as the wild-
type (top gel) or mutated (bottom gel). The Kd values were determined on the basis
of a minimum of three independent gel mobility shift experiments.
interacts with a different guanosine in this new sequence, although it would be in a
different location in the helix. Interestingly, the 5' -AGUCU-3' sequence and the putative
MBNLI consensus sequence (YGCUUY) (17) are similar in that both contain a
guanosine followed by a run of pyrimidines. The major difference between the motifs is
the presence of the adenosine in the SELEX motif. Also importantly, the SELEX 5'-
AGUCU-3' motif is involved in all Watson-Crick base pairs, while the YGCUUY motifs
in cTNT, when base paired, contain both Watson-Crick base pairs and pyrimidine-
------------------------
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pyrimidine mismatches (22). However, in the SELEX RNA 20, a pyrimidine-
pyrimidine mismatch 3' to the 5' -AGUCU-3' motif (U5?-C64) appears to be important
for binding because if the mismatch is replaced with a G-C base pair, the level of binding
is reduced 30-fold (Figures 6 and 8).
Although stem-loop 2 is clearly important for Mbl binding, the 5' - and 3' -single-
stranded tails are also important for binding (Figure 5). These tails could be involved in
tertiary interactions with other regions of the RNA that are difficult to monitor with gel
mobility shift assays and footprinting. It is possible that the G-rich regions of the 5' -tail
interact with loop 1 or the 3'-tail and aid in loading of Mbl onto the RNA or proper
folding of the RNA, and upon removal, these interactions are lost. Apparently, the tails
are specific to the SELEX RNA because the addition of the tails to the CUG repeats did
not enhance binding (data not shown). The 50-nucleotide cTNT RNA also contains 5'-
and 3' -tails that could be aiding in the formation of the correct RNA structure recognized
by Mbl.
A comparison of the SELEX RNA 20 with the human cTNT RNA reveals a site
that the two RNAs may share. As shown in Figure 8, the loop and upper portion of stem-
loop 2 of RNA 20 and the upper portion of the cTNT RNA are quite similar in sequence
and structure, assuming RNA 20 and cTNT adopt similar three dimensional structures.
Both of these RNAs contain two pyrimidine-pyrimidine mismatches (positions 1 and 3)
with a potential U-G wobble base pair between them (position 2). Below the position 3
mismatches are two additional base pairs, with position 5 being a C-G base pair in both
RNA 20 and the cTNT structures. MBNLI has also been shown to bind a structured
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RNA site within the mouse Tnnt3 pre-mRNA and regulate splicing through this site
(23). Mutational analysis revealed the recognition site for MBNLI as being a stem-loop
position f\ f\
1 C U U C C-G
2 U.... G U-G G-C
3 U C C C C C
4 U-A G-U G-C
5 C-G C-G U -A
5' A G U 3' 5' 3' 5' 3'
RNA #20 cTNT Tnnt3
Figure 8. Comparison of three stem-loop binding sites for the muscleblind family
of proteins. From the SELEX RNA 20, a portion of stem-loop 2 is shown beginning
with the highly enriched 5' -AGUCU-3' sequence (RNA 20). The upper portion of the
cTNT stem-loop structure (cTNT) is shown. The upper portion of the mouse Tnnt3
stem-loop structure (Tnnt3) is shown (23). The position and numbers refer to base pairs
or mismatches in the structures to the right. The bold nucleotides highlight the sequence
similarity between the structures. The dashed line indicates a potential G-U wobble
base pair in RNA 20.
structure within a larger RNA structure. This stem-loop also contains a pyrimidine-
pyrimidine mismatch but lacks the sequence similarity to SELEX RNA 20 and the cTNT
RNA (Figure 8). The comparison of these three RNAs indicates Mbl and MBNLI bind
structured RNA stem-loops and that there is significant flexibility in the composition of
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the sequences, which makes it challenging to identify a consensus sequence within the
context of a stem or stem-loop.
We speculate that stem-loop structures containing correctly positioned guanosines
and pyrimidine-pyrimidine mismatches will be found as the binding sites in Mbl's
endogenous targets such as tun and a-actinin pre-mRNA. These transcripts were
recently shown to be mis-spliced in Mbl mutant flies (3). Vicente and colleagues (4)
proposed a CUG-rich region downstream of a regulated exon in the a-actinin pre-mRNA
as a potential binding site forMbl. This region can potentially fold into a stem-loop
containing pyrimidine-pyrimidine mismatches (4). In preliminary studies, we have found
a lIS-nucleotide RNA, containing this CUG-rich region, binds Mbl with weaker affinity
compared to CUG repeats, SELEX RNAs, and the cTNT RNA (data not shown).
Although our study has improved our understanding of how Mbl binds RNA, it is clear
that additional investigations of Mbl- and MBNL-RNA interactions are required to reach
a point at which binding sites can be predicted.
Zinc finger proteins, other than muscleblind proteins, are capable of recognizing
complex RNA structures. There are several classes of zinc finger proteins, including
CzHz, CCCH, and CCHC, that bind RNA (31). Some zinc finger proteins are
promiscuous and bind double-stranded DNA and single- and double-stranded RNA (32),
while others, like Mbl, bind specifically to double-stranded RNA. An example of a zinc
finger protein that binds RNA is TISlld. TISlld binds single-stranded RNA with a 5'-
UAUU-3' motif by making specific stacking interactions between aromatic side chains
and the RNA bases (32). This mode of binding by TIS lId is probably different than
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Mbl's mode of binding due to its double-stranded RNA targets. However, the HIV
nucleocapsid protein (NC) contains two zinc fingers of the CX2CX4HX4C type and has
been found to recognize a variety of stem-loop structures from the HIV RNA (33, 34).
There are three exposed guanosines in the loop portion of stem-loop 3 from the HIV '4J-
RNA recognition element that directly interact with multiple amino acids positioned by
the zinc fingers of the HIV NC protein (35). The zinc fingers of Mbl may be performing
a role similar to the role of the HIV NC zinc fingers in that the amino acids are positioned
for specific recognition of the guanosines in the SELEX RNA sequences and endogenous
RNA targets of Mbl.
The mutagenesis with the CUG repeats and the cTNT RNA revealed that Mbl is a
specific RNA binding protein and is apparently more specific than MBNLI since it
displays a greater degree of specificity for both the CUG repeats and the cTNT RNA
substrates. The primary difference between these two muscleblind proteins is that Mbl
contains only two zinc fingers while MBNLI contains four zinc fingers. One possibility
is that the two additional zinc fingers of MBNLI are nonspecific RNA binding domains,
resulting in a less discriminate RNA binding protein. The third and fourth zinc fingers in
MBNLI appear to be related to the first two of Mbl and MBNLI in sequence and could
be the result of a duplication event (36). In future studies, it will be interesting to
determine if muscleblind proteins with two zinc fingers are generally more specific RNA
binding proteins compared to muscleblind proteins with four zinc fingers. This minimal
Mbl protein construct should prove useful for structural studies and in further dissecting
the RNA binding abilities of this important protein as well as the identification of its
binding sites in Drosophila RNAs.
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CHAPTER III
DOPED SELEX WITH MBNLl REVEALS A MOTIF USED TO IDENTIFY
NOVEL MBNLl BINDING SITES
This chapter is currently being prepared as a manuscript with the help of Devika P. Gates
and Rodger B. Voelker. I have performed the majority of the experiments thus far, with
the help of Devika P. Gates. Rodger B. Voelker performed the bioinformatics (highly
enriched k-mer analysis and positional selection analysis). 1. Andrew Berglund aided in
experimental design and will be last author on the manuscript.
INTRODUCTION
Alternative splicing is essential for creating a diverse, functional proteome.
Approximately 74% of human genes are predicted to be alternatively spliced (1). The
proteins accountable for regulating alternative splicing, alternative splicing regulators, are
active in tissue- and developmentally-specific fashions. A small group of alternative
splicing regulators have been identified, they include NOVA, the CELF family, the FOX
family and the muscleblind-like (MBNL) family of proteins. NOVA is a neuron-specific
alternative splicing regulator that binds to YCAY clusters in or near regulated exons and
promotes exon inclusion or exclusion (2, 3). The FOX family of proteins are expressed
in brain, heart and skeletal muscle and bind the UGCAUG RNA motif. The location of
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binding, by the FOX family of proteins, CUG-BP (in the CELF family) and NOVA,
relative to the regulated exon determines whether the exon is excluded or included in the
mRNA(3, 4). Based on hundreds of predicted FOX-I/2 binding sites, FOX-I/2 binding
upstream of the regulated exon promotes exclusion while binding downstream promotes
inclusion (4). CUG-BP regulates many of the same transcripts that MBNLI does,
however, it is in an antagonistic fashion. For example, MBNLI binds upstream of exon 5
in the cardiac troponin T (cTNT) pre-mRNA and promotes exon exclusion while CUG-
BP binds downstream of exon 5 and promutes inclusion (5, 6).
The muscleblind family of proteins are highly conserved across metazoans,
especially in the zinc finger domains, and bind RNA in a specific fashion (6-8).
Muscleblind is implicated in myotonic dystrophy as it becomes sequestered to aberrant
RNA transcripts in the nucleus of patients. In myotonic dystrophy type 1 (DMl),
MBNLI becomes sequestered to CUG repeats and in myotonic dystrophy type 2 (DM2),
to CCUG repeats (9, 10). This sequestration is sufficient to cause a deficiency of
MBNLI binding to pre-mRNA targets. This lack of binding by MBNLI causes
important developmentally-specific transcripts to become mis-spliced and leads to
symptoms of DM. For example, insulin receptor (IR) and chloride ion channel (CIC-l)
pre-mRNAs are mis-spliced in DMI patients leading to inappropriate expression of fetal
isoforms or degradation of the transcript (11-13). The lack of appropriate IR and CIC-I
splice isoforms in DMI patients is thought to lead to the symptoms of insulin resistance
and myotonia, respectively.
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CUG repeats form stem-loop structures with pyrimidine-pyrimidine
mismatches (14,15). MBNLI has a preference for weak stem-loops containing G-C base
pairs, G-U wobble base pairs and pyrimidine-pyrimidine mismatches (6, 7). This
preference is apparent because MBNLI binds CUG repeats, CCUG repeats and a
MBNLI binding site in cTNT pre-mRNA, all of which are capable of forming stem-loops
(6, 15). MBNL1's binding site in cTNT is a 32 base region (32mer) about 35 bases
upstream of exon 5 (6, 16). MBNLI promotes the exclusion of exon 5 which produces a
splice product found in adult tissue. However, in DM1, MBNLI is sequestered and
causes cTNT exon 5 to be included aberrantly and produces a splice product normally
found in fetal tissue (17). Several other pre-mRNA transcripts are regulated by MBNL1,
including SERCA1, MBNLI and IR (for review see(10, 18». However, the only known
human MBNLI binding site is the one in cTNT. The identification of additional MBNLI
RNA binding sites would allow for a deeper understanding of MBNLI 's RNA binding
specificity. This will help identify pre-mRNA targets regulated by MBNLI and to
predict MBNLI binding sites within these targets.
To identify the important residues in the cTNT binding site, doped SELEX was
performed on this RNA. The doping incorporated the endogenous cTNT binding site
sequence at a rate of 51 % for each of the 32 residue positions. After 5 rounds, the
majority of SELEX sequences tested bind MBNLI with high affinity, similar to
MBNLI 's affinity for the cTNT site. The SELEX sequences revealed selection
throughout the doped region. The most pronounced selection occurred on the left side of
the cTNT binding site stem; specifically, the selection lead to an over-enrichment of
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UGCUU 5-mers in the 82 sequences. We used this motif to identify three potential
MBNLI sites in MBNLI and SERCA1 pre-mRNAs. The potential MBNL1 and
SERCA1 sites are within 200 bases of MBNLl-regulated exons and MBNL1 binds these
40 nucleotide sites with high affinity in vitro.
MATERIALS AND METHODS
SELEX
The MBNLI construct used is truncated and includes residues 1-260 and an N-
terminal GST tag. This construct, termed MBNLI throughout the paper, binds RNA as
tightly as the full length version (6). For purification of MBNL1 see Warf and Berglund
'07. The DNA template used for the SELEX (Systematic Evolution of Ligands by
Exponential Enrichment) (19) experiment was the following 81-mer oligonucleotide: 5'-
GGGAATGGATCCACATCTACGAATTC(CCTGTCTCGCTTTTCCCCTCCGCTG
CGGCCAC)AAGACTCGATACGTGACGAACCT -3'. The oligonucleotide depicted
here contains the 32 nucleotide MBNL1 binding site in cTNT (in bold) flanked by two
constant regions. To create the SELEX pool 0, the nucleotides in parenthesis were
randomized; 51 % of the time the original nucleotide was kept at each position and the
other 49% of the time each position was varied to incorporate an equal mix of the other
three nucleotides. The forward primer for the SELEX was 5'-
GATAATACGACTCACTATAGGGAATGGATCCACATCTACGA-3' and the reverse
was 5'- AGGTTCGTCACGTATCGAGTCTT -3'. The initial PCR reactions were
amplified by 8 rounds of PCR and calculated to approximately 1xlO14 molecules. The
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transcription reactions were done under the following conditions: 500 ng/JlL template,
40 mM Tris pH 7.9,26 mM MgCI2, 2 mM spermidine, 10 mM NaCl, 5 mM of each
nucleotide, 0.1 Jlg/lOO JlL yeast pyrophosphatase, ~2 mg/mL T7 polymerase, and 40 mM
DTT . The transcription reactions were performed with trace amounts of [a_p32] CTP for
monitoring purposes. After transcription, reactions were treated with DNase for 1 hr at
37°C, gel purified, ethanol precipitated and run over a Bio-Spin-6 size exclusion column
(Bio-Rad). For each round, the appropriate concentration of MBNLI was bound to 20 !-tL
of glutathione-agarose beads at 4°C for 15 min, then washed 1 time with 200 !-tL SELEX
binding buffer (100 mM NaCl, 20 mM Tris pH 7.5, 5 mM MgCI2, 0.02% triton x-lOa and
5 mM DTT added the day of use). All washes were done in a similar manner. Round 6
was performed in the same way but with a higher NaCI concentration (150 mM NaCI
instead of 100 mM NaCl, the other reagents remained constant). The RNA was heated in
SELEX binding buffer at 95°C for 3 min and placed immediately on ice for 10 min. The
protein used throughout the paper was a truncated version of MBNLI with amino acids
1-260 and an N-terminal GST tag as in Warf and Berglund (6). The MBNLl-bound
beads were incubated with the RNA at 25°C for 20 min. The beads were washed 1 time
with 200 !-tL of SELEX binding buffer at 25°C and RNA was released and collected from
the beads by a phenol-chloroform extraction and subsequent ethanol precipitation. The
collected RNA was reverse transtribed using AMY reverse transcriptase, AMY buffer,
8.8 JlM reverse primer, and 2/3 of the RNA isolated after the round for 1 hr at 42°C.
After the reverse transcription was complete, the DNA was amplified by 11 PCR cycles.
The DNA was transcribed and the SELEX cycle repeated seven times with the
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concentration of RNA and MBNL varying according to Table 1. After the rounds
were completed, individual clones were isolated by TOPO cloning (Invitrogen) and
sequenced.
Table 1: Concentration of RNA and
Protein used for rounds of SELEX
round
1
2
3
4
5
6
7
20
9.8
8
2
1
0.5
0.25
Protein (!-tM)
20
4.9
2
0.33
0.13
0.05
0.025
Labeling ofRNA Oligomers for Gel Mobility Shift Assays
RNA oligomers were transcribed from templates using T7 RNA polymerase and
[a_p32] ATP. RNA oligomers were kinased using Polynucleotide Kinase and [y_p32] ATP.
Gel Mobility Shift Assay
Gel mobility shift assays done as in Warf and Berglund 2008, with modifications
as follows (6). RNA (8 ]lL) was snap annealed in (75 mM NaCI, 5 mM MgCI2, 15 mM
Tris pH 7.5,0.25 mM B-ME), mixed with 2]lL of protein for final reaction conditions of
175 mM NaCl, 5 mM MgCI2, 20 mM Tris pH 7.5, 1.25 mM B-ME, 10% glycerol, 2
mg/mL BSA, 0.1 mg/mL heparin and trace amounts of bromophenol blue. The binding
reactions were incubated for 10-25 minutes at room temperature and 2-4 ]lL were loaded
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onto a 6% acrylamide gel (6% 37.5:1 acrylamide:bisacylamide, O.5X TB). Gels were
run for 35 min at 170 V.
Positional Selection
The selective pressures on individual positions was determined by calculating the
Z-score for the observed nucleotide frequencies in each position versus the expected
frequencies if there was no positional selective pressures. For each position the expected
mean was calculated using the maximum likelihood estimate for the mean (based upon
the theoretical probabilities for each position) and the standard deviation was calculated
using the standard deviation for the binomial distribution, ,Jnp(l - p) where n is the
number of observations (which in this case equals 82), and p is the probability of the
nucleotide occurring in that position. These means and standard deviations were used to
calculate a Z-score using Equation 1. This equation is allowed since the expected
numbers are always greater than 10, in this sized sample, which means that the
underlying distribution approaches the Gaussian distribution.
K-mer Enrichment
All k-mers from 3 to 5 nt were counted in the final 82 SELEX sequences,
including the random sequence plus 5 nt of the constant flanking sequence. The inclusion
of the flank allows one to analyze k-mers that overlap with the edges of the constant
sequence. To calculate a Z-score for the observed vs. expected occurrences we used
Monte-Carlo simulation to estimate the mean (f-t) and standard deviation ( a) for the
occurrence of all k-mers in 1000 independent populations of 82 sequences constructed
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using the same random biases used to synthesize the oligos used as input in the SELEX
experiment. The Z-score (z) for each k-mer was calculated according to equation 1 where
fJ, is the mean observed over the random samples, a is the standard deviation for the k-
mer occurrence within the random samples, and x is the observed occurrence within the
population derived from SELEX.
X-/-l
z=--
a
RESULTS
(Equation 1)
MBNL1 Binding Site in cTNT Intron Provides a Template for a Doped RNA SELEX
The 32 nucleotide MBNL1 binding site upstream of exon 5 in cTNT pre-mRNA
was used as the template for generating SELEX pool 0 (6, 16). Each position contains
the wildtype residue 51 % of the time and 48% of the time contains the other 3 residues
equally (16% each). For example, the first position in the 32 nucleotide region is C, so in
51 % of the RNA sequences, it will remain a C, while the other 48% of the time A, G or U
is incorporated at that position. This allows MBNL1 to sample other possible residues at
each position with a bias toward the endogenous residue. The 32 endogenous nucleotides
are flanked on each side by constant regions, 26 nucleotides on the 5' side and 23
nucleotides on the 3' side for priming and transcription purposes (Figure 1A). The
MBNL1 construct used is truncated and includes residues 1-260 and an N-terminal GST
tag. This construct, termed MBNLI throughout the chapter, binds RNA as tightly as the
full length version (6).
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The initial rounds of selection were carried out under standard conditions (100
mM NaCI, 5 mM MgCI2, 0.02% triton x-lOO, 1 mM DTT, 20 mM Tris pH 7.5) with a
slightly lower sodium chloride concentration in order to retain roughly 5-10% RNA
bound after each round. Binding affinity of MBNL1 was weak for pool zero with a Kd
A
eCCe
U U
Uu cC'- (51%C. 16%G/U/A)
U-G
C C
G-U
C-G
U C
C-G
U-G
26 bases ~- CC 23 bases
5'~cc Ac~3'
'-y--'
32 bases
B
WTtemplate
..........._d
Round 0
____1 Round 5_~.d
Round 7
..........._1
Figure 1. Round 5 and round 7 of SELEX RNA oligomers bind significantly
tighter than round 0 RNA oligomers. (A) The template used for the SELEX
included MBNL1 's cTNT intronic binding site (the 32mer stem-loop) in the center
of the template and flanking constant regions. The central 32 bases were doped at
each position with 51 % of the endogenous base and 49% of the other three
nucleotides equally (16% each). (B) Gel mobility shift assays showing MBNL1
binding to the endogenous cTNT template, round 0, round 5 and round 7 RNA
sequences. The concentration of MBNL1 is shown at the top of each lane in nM.
greater than 1.2]lM (Figure IB). The binding buffer was changed at round seven to
higher salt (from 100 mM NaCl to 150 mM NaCl) to make the conditions more stringent.
Binding affinities increased after each round until round seven (Figure 1B). 96 sequences
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were obtained for round zero, 82 sequences for round five and 76 sequences for round
seven in order to analyze the evolution of sequence selection over the subsequent rounds.
Pool zero was sequenced to insure that there was no bias in the initial pool other than the
designed doping. A usage frequency analysis at each position revealed that pool zero
was very close to the doping design (data not shown). Pool five RNA sequences were
analyzed more in depth as they showed promise for providing a consensus motif.
Analysis of pool seven is discussed in the appendix.
After five rounds, the approximate affinity of the pool was similar to the
endogenous cTNT binding site template (Figure IB). Eighty-two clones from round five
were isolated and sequenced. The sequences were grouped according to Jalview
dendrogram analysis based on percent identity (20). Such analysis showed only one
obvious outlier, with the majority containing relatively close sequence similarities
(Figure 2). From the dendrogram, blocks of high sequence similarity are apparent. There
are some regions of moderate sequence identity in the 3' region, however, the region of
highest identity similarity is the 5' half of the sequences (Figure 2B). There were no
duplicates in this round indicating that over-selection did not take place. Also, the
sequence most closely related to the endogenous cTNT template (D03) contained six
bases that differed (Figure 4). This was not surprising, as pool zero started out with a 1 in
2,279,098,388 chance that a sequence would be identical to the endogenous template.
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Figure 2. The 82 SELEX sequences from round 5 fell into one main group.
(A) Dendrogram showing the 32 nucleotide randomized region of the SELEX
sequences aligned based on sequence identity. The wild type cTNT site is
included. (B) The sequences ordered based on the dendrogram in (A), with darker
blue representing higher sequence identity.
Tile Majority ofSELEX Sequences Bind MBNLJ With High Affinity and Provide
a Consensus Mot!fof5'-YGCUU-3'
To understand the selection for and against certain nucJeotides at specific
locations along the stem, a Z-score analysis was performed at each residue position,
taking into account the doping bias (Figure 3A). A positive Z-score indicates a positive
65
selection for that particular nucleotide, while a negative Z-score indicates a negative
selection for that nucleotide. Most positions have a positive selection for T (U) and
negative selection against A, which follows with the fact that the cTNT binding site has
very few adenosines and is uracil rich. This indicates that MBNLI prefers uracil over
adenosine in its binding sites. The majority of positions with selection are located in the
5' half of the sequence, which can also be thought of as the left side of the stem (Figure
3B). The first two positions (Cland Cz) show strong selection to remain Cs. From
analysis of the predicted folds of many of the SELEX sequences, they often form base
pairs with the constant region, which is most likely why they were selected to remain as
Cs, not necessarily because MBNLI selected them as part its recognition site. However,
they may playa role in setting up the proper structure for MBNLI binding. There is very
little selection throughout the loop region (UlrCzl)' presumably because MBNLI binds
regions of structured RNA. It is intriguing that there is also less selection in the 3' half of
the sequence. G27 was selected to become a U, which would no longer allow it to base
pair with C6 . This is consistent with the finding by Warf and Berglund that MBNLI
binds with higher affinity to RNAs that contain a mix of mismatches and base pairs, not
complete base pairing (6). With such positive selection in the left side of the cTNT stem
and less selection in the right side of the stem, it is possible that MBNLI prefers very
little structure.
Reasoning that the four bases from the endogenous site (G9 -U lZ) that were
selected to remain the same were probably important for MBNLI 's binding, they were
included in the consensus sequence of 5' -CCNNCUNUG9CUU-3'. Using a Z-score cut
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off of 4 to define positive selection, several bases 5' to G9 were also selected for, and
are subsequently included in the motif (Figure 3A). Us, C6 and Us were all selected to
switch from the pyrimidine in the endogenous sequence to the other pyrimidine. For
example Cs was selected to become a U and Us selected to become a C. It is possible that
MBNL1 prefers a short run of pyrimidines 5' of the 5' -G9CUU-3'. However, MBNL1
bound, weakly to a 40mer containing the aforementioned motif flanked on the 5' end by
12 uracils and 12 cytosines on the 3' end (Figure 3D). This indicates that some structure
is required for binding by MBNLl. Assuming that MBNL1 interacts with approximately
five bases when binding RNA, like other RNA binding proteins such as Nova and FOX1,
a consensus motif of 5'-YGCUU-3' is useful (21, 22).
In order to determine if 5'-YGCUU-3' was over-enriched in the 82 round 5
SELEX sequences in comparison to pool 0, an analysis of different 3-mers, 4-mers and 5-
mers was performed (materials and methods section, k-mer analysis). The analysis
included the number of expected occurrences for each k-mer (based on 1000 randomly
generated sets of 82 sequences) and the observed number of occurrences in the 82
SELEX sequences, taking into account the doping bias (Table 2). The Z-scores range
from 14.8 to 33.1, indicating high statistical significance. The UGCUU S-mer is clearly
over-enriched with 61 occurrences in the SELEX sequences compared to only 3.1
expected occurrences. In addition, many shorter permutations of UGCUU, such as GCU
and GCUU, were highly enriched. This is strong evidence that 5'-YGCUU-3' was
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selected for by M8NU, with a preference for a U in the Y position. This is interesting
as the endogenous cTNT binding site contains 5'-YGCUU-3' with a C, not a U, in the Y
position. This further supports the argument that MBNU most likely does not have a
strong preference for either pyrimidine in that position of the motif.
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Figure 3. Regions of positive and negative selection reveal a consensus
binding sequence on the left region of the cTNT stem. (A) Z-score analysis was
performed at each position within the doped region. A negative z-score indicates
negative selection and a positive z-score indicates positive selection. The bars
representing different nucleotides are stacked on top of each other. The
endogenous cTNT sequence is shown below. (8) The stem-loop of the cTNT
binding site is shown with colors matching to the consensus sequence in (C). The
arrows pointing away from the residue indicate that negative selection occurred for
that base to change from its original residue to the residue at the head of the arrow.
(C) The original consensus sequence identified using the z-score graph in (A) and
taking 1 as the cutoff for statistical significance. (D) Gel mobility shift assay of a
single stranded version similar to the motif shown in (C). The RNA sequence is:
5'-CCUUCCUCGCUU-3' with 12 uracils flanking on the 5' side and 12
cytosines flanking on the 3' side to ensure single stranded RNA.
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The majority of SELEX sequences (74 out of 82) contain one to four 5'-
YGCUU-3' motifs (Figure 4). The motifs are mainly located in the 5' half of the
Table 2. Highly Enriched k-mers Found in SELEX Sequences
k-mer expected observed Z-score
UGCUU 3.1 61 33.1
GCUU 14.6 116 27.6
UGCU 12 100 26.1
GCUUU 4.8 51 22.1
CUGCU 4.5 50 22
GCU 56.1 197 19.33
UGC 51.9 169 17.9
UUGC 13.8 69 15
CUU 58.3 160 14.8
Observed is the total occurrences of the k-mer within the sample of
82 SELEX sequences. The expected number is the mean number
observed for 1000 sets of 82 random sequences that are equivalent in
size to the SELEX sequences, and, for which, the background
probabilities for each nucleotide position are the same as used during
synthesis of the starting SELEX population. The Z-score was
calculated using the mean and standard deviation derived from the
1000 sets of random sequences. The 9 k-mers in the table had the top
3 highest Z-scores within the respective length categories (3-mer, 4-
mer, 5-mer) The k-mers are ordered by decreasing Z-score.
randomized region with around half of them in the same location as the wild type cTNT
5'-CGCUU-3' motif (Figure 4, column 1 and 2). This is consistent with the Z-score
results which demonstrate that a stronger selection took place in the 5' half of the
sequence. However, many of the sequences show that MBNLI selected for the 5'-
YGCUU-3' motif to change position with respect to the 5'-YGCUU-3' motif in the wild
type cTNT. In some cases, this change is a slight shift of the position of the motif in
comparison to the location of the wild type motif, whereas in others a whole new second,
third or forth additional motif appears nearby or in a different region. There are roughly
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equal numbers of 5'-UGCUU-3' and 5'-CGCUU-3' motifs, again indicating that
MBNLl simply prefers a pyrimidine 111 the position just 5' to the G.
Binding studies were performed on 16 of the 82 sequences to determine the
affinities of these sequences to MBNLl. Almost all sequences have affinities roughly
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Figure 4. Most SELEX sequences contain at least one 5'-YCGUU-3' motif and
bind with high affinity to MBNLl. The 5'-UGCUU-3' motifs are highlighted in
green and the 5'-CGCUU-3' motifs in pink. The numbers to the right of the
sequences indicate K" values (nM) of MBNLl binding. The dissociation constants
displayed are based on binding to sequences containing the constant regions
(81 mers). The ~ indicates only one or two gels were used to calculate the binding
affinity, otherwise at least three gels were analyzed. The top of each column
contains the endogenous sequence (labeled WT and highlighted in yellow) for
comparison. Note- T and U are used interchangeably, both represent uracil.
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equal to or higher than the endogenous cTNT binding site (Figure 4 and 5). Only two
did not bind MBNLI at all, showing that the selection was successful. The binding
affinities to SELEX sequences that contain 5'-YGCUU-3' are between 0.9 nM and 37
nM, similar to the wild type cTNT site which has a dissociation constant (Kd) of 31 nM.
Interestingly, two of the three sequences that lack the motif, don't bind MBNLI,
indicating the importance of the motif to MBNLI binding (Figure 4 and 5). The one
sequence (H05) that doesn't have 5' -YGCUU-3', but still binds MBNLI, contains 5'-
YGCUG-3' which has a G in the position of the last U. This motif (5'-YGCUGY-3') is
also in the 3' region of the wild type cTNT binding site (the right side of the stem) and is
postulated to be an MBNLI binding site by Ho et al. (16).
Table 3. Binding Affinities of Selected SELEX Sequences
and the Wild Type cTNT Binding Site
sequence Kd 8lmer (nM) Kd 32mer (nM)
DOl 25 ±6
C03 ",0.9
EOI ",3
B07 ",3 "'0.5
A04 6±5 ",84
B08 >1.2#M
H05 ",31
Cl2 >1.2 #M
COl ",I
F06 1 ± 0.1 ",2
B01 '" 37
H06 4±4
A02 ",6
B02 '" 37
E12 17 ± 11
WT cTNT binding site 31 ±22 21 ± 11
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It is possible that the constant regions are playing a role in the binding of
MBNLI to the SELEX sequences. There is a slight decrease in affinity for the
endogenous cTNT SELEX template (8lmer, ~ '" 31 nM) compared to the 32mer
endogenous cTNT site (32mer, Kd ", 21 nM), indicating that the flanking constant regions
have a slight affect on MBNLI binding (Table 3). Similar studies were performed on
several of the SELEX sequences by removing the flanking regions and determining
binding affinities to the equivalent 32mer (Figure 5B). The F06 32mer shows similar
binding to the equivalent 8lmer while A04 and B07 shows decreased binding and
increased binding to MBNLl, respectively. These studies show that the conserved
flanking regions can either positively or negatively affect MBNLI binding in a subset of
SELEX sequences. However, the binding effects caused by the flanking regions are
minor, except for A04 in which binding is reduced approximatelylO-fold for the 32mer
compared to the affinity of the 8lmer (Table 3).
Mutations in the 5'- YGCUU-3' Consensus Motif Decrease MBNLI 's Binding Affinity
To determine ifMBNLl is recognizing 5'-YGCUU-3' as a binding site,
mutations were made in the motif of two SELEX sequences, F06 and E12. The 5'-
CGCUU-3' motif in F06 was mutated to 5'-UCCAU-3', with the 3 bases mutated in
bold. The 5' -UGCUU-3' motif in E12 was mutated to 5' -ACCAU-3', with the 3 bases
mutated in bold (Figure 6). The mutations significantly decreased binding, indicating
that MBNLI requires 5'-YGCUU-3' to bind tightly. This could be because MBNLI
recognizes and binds the motif as a sequence, or the motif is necessary for setting up a
structure (Figure 6).
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Novel Binding Sites Identified in pre-mRNAs Regulated by MBNLI
With the cTNT intronic site the only known binding site of MBNLI in a human
endogenous transcript, we sought to find additional sites that contain the 5'-YGCUU-3'
consensus motif. Exons known to be regulated by MBNLI were selected and 5'-
YGCUU-3' was searched for in the 200 bases of intronic sequence immediately upstream
and downstream of the regulated exon. Two sites in MBNLI intron 6 and one site in
SERCAI intron 22 have been identified. Site #1 in MBNLI is located 75 bases upstream
of the alternatively regulated exon 7 (counted from the 3' splice site to the G in 5'-
YCGUU-3') and the second site is found 179 bases upstream within the same intron.
Interestingly, these two sites flank a potential polypyrimidine tract and branch point
sequence that could influence how MBNLI regulates the splicing of the downstream
exon. The potential MBNLI site found in SERCA pre-mRNA is located 135 nucleotides
downstream of exon 22 and may promote exon 22 inclusion (Figure 7B). All three
potential sites include bases additional to the 5' -YCGUU-3' motif that are found in the
longer motif of 5' -CCNNCUNu'G9CUU-3' identified from the Z-score analysis (Figure
3A and Figure 7A). The MBNLI site #1 and the SERCAI site both have runs of
pyrimidines 5' to the 5'-YCGUU-3' motif that could be playing a role in MBNLI
binding. Gel mobility shift assays to 40mers containing the three potential sites (MBNL
site #1 and #2 and SERCAI site) were performed (Figure 7C). MBNLI binds MBNLI
site #1 40mer with a Kd of 2 ± 1 nM and binds the SERCAI 40mer with a Kd of 15 ± 6
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Figure 5. SELEX sequences bind MBNLl with high affinity with or without the
constant regions. (A) Gel mobility shift assays of the endogenous cTNT site
flanked by the constant regions (cTNT with constant; 81mer) and five SELEX
sequences. The MBNL1 concentrations (nM) are labeled at the top of each lane. (B)
The flanking constant regions have variable affects on the binding affinities of
MBNL1 to SELEX sequences. The flanking constant regions have been removed
from three SELEX sequences and the wild type cTNT site (cTNT without constant;
32mer) and gel mobility shift assays performed to determine the Kd (labeled below
each gel). The MBNL1 concentrations (nM) are labeled above each lane.
nM. MBNL1 binds both with high affinity, well within the range of the known MBNL1
binding site in cTNT, which has a Kd of 21 ± 11 nM.
DISCUSSION
The identification of key residues in MBNL1's binding site in cTNT provides a
better understanding of MBNL1's RNA binding specificity. A doped SELEX was
performed using the 32 base cTNT binding site. By round 5, the pool of RNA sequences
bound as tight as the wild type cTNT binding site (Figure IB). The 82 sequences
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identified from round 5 group together based on similar sequence identity, with one
outlier and no duplicates, indicating that over-selection did not occur (Figure 2). In
A
11~1
F06 F06 UCCA E12 ACCA
<
(I 1.1 15 50 100 200 (I IJ 15 50 100 200 (I 0.9 6 30 200 1200 0 IJ 25 50 100 100
B
0.98 nM - 263 nM 16.5 nM weak
F06 CCOATCCCGCrrATGCCATCCGCTGCAGTCAC
F06UCCA CCGATCCUCCATATGCCATCCGCTGCAGTCAC
>E12 CCGCTGCTGCTTATTGCCTAACGl\CCGTGTTG
E l2ACCA CCGCTGCACCATA'l'TGCCTAACGACCGTGTTG
Figure 6. Mutations to the S'-YGCUU-3' motif in SELEX sequences decrease
binding. (A) Gel mobility shift assays of SELEX sequences F06 and El2 and
corresponding mutants. The I\IIBNL I concentrations (nM) are labeled at the top of
each lane. (B) F06 and EI2 each contain one occurrence of 5'-YGCUU-3'
highlighted in pink (F06) or yellow (EI2). Mutations are shown in the sequence
below the original sequence in bold. Binding studies in (A) were pelformed with
F06 and E12 that contain the constant regions (81 mers) although only the 32mers
are depicted in (B).
addition, 96 sequences from pool 0 were sequenced and showed no bias additional to the
doping bias (data not shown). Strong blocks of similar sequence identity are apparent in
the 5' region of most of the SELEX sequences, indicating a selective pressure in that
region (Figure 38).
This selective pressure is also apparent when the Z-scores for each position are
analyzed. MBNU generally selects uracil for binding, while adenosine is generally
selected against in the SELEX sequences (Figure 3A). Also, over half of the residues in
the 5' half of the randomized region show positive selective pressure, which corresponds
to selective pressure on the left side of the stem-loop of the cTNT binding site (Figure
38). This pressure is clear when each 5'-YGCUU-3' motif position is compared to the
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position of 5'-CGCUU-3' in the cTNT wild type sequence. Most motifs remain in the
same location as the wild type motif, or shift slightly to the 5' side (Figure 4). Using 4 as
a Z-score cut off, a motif of 5'-CCNNCUNUG9CUU-3' is apparent in the 5' half of the
SELEX sequences (Figure 3C). With a bias in selection in the left side of the stem, and
less selection in the right side, based on these findings it is possible that MBNL1 prefers
to bind to weakly structured or single stranded RNA. A single stranded 40mer RNA
containing the aforementioned motif with a 5' uracil tail and a 3' cytosine tail, was tested
for binding to MBNL1. This single stranded motif RNA bound weakly to MBNL1
(Figure 3D). However, a small portion of the RNA bound at a low MBNL1
concentration, 0.9 nM, suggesting a portion of the RNA adopts a conformation that is
favorable for binding by MBNLl. The 5' -YGCUU-3' motif is important for binding by
MBNL1 as 3 mutations in the motif decrease MBNL1 binding affinities in F06 and E12
SELEX sequences. This indicates MBNL1 requires 5'-YGCUU-3' for high affinity
binding to these sequences.
A k-mer analysis comparing the number of expected specific k-mers to the
number of observed was performed using the 82 SELEX sequences. UGCUU and
shorter derivatives were clearly enriched, with UGCUU having a Z-score of 33.1 (Table
2). This indicates that MBNL1 most likely selected to bind to this motif. Thirteen out of
sixteen SELEX sequences tested bind MBNL1 with high affinity, and all contain one to
four 5'-YGCUU-3' motifs. The two that don't bind MBNL1, don't contain the motif,
indicating the importance of the motif. Only one, H05, binds MBNL1 and doesn't
contain 5'-YGCUU-3' (Figure 4). However, it does contain 5'-YGCUGY-3', a
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previously-identified MBNLI binding motif, which may account for the high affinity
(/6). The 5-mer UGCUG occurred 17 times and was only expected to occur 3.2 times in
the k-mer analysis, indicating enrichment of the previously identified motif 5' -UGCUG-
3' (data not shown).
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Figure 7. Novel MBNLI binding sites identified near MBNLl-regulated exons
in MBNLI and SEI~CAI pre-mRNA. (A) Shown is the potential secondary
structures of the 40mer binding sites in MBNLl and SERCA 1 transcripts. On the
left is the secondary structure of MBNLl 's binding site (32mer) upstream of exon 5
in cTNT pre-mRNA (Waif and Berglund '07). The colors indicate residues found in
the original consensus motif (Figure 3C). The dashed box in MBNL site 112
indicates a potential FOX-I/2 binding site. (B) The schematics indicate where the
potential binding site is located relative to the MBNLl-regulated exon. (C) Gel
mobility shift assays of the 32mer RNA, in the case of cTNT, or 40mer RNA in the
case of MBNLI site #1 and #2 and SERCAI site, bound to MBNLl.
The constant flanking regions compose slightly more than half of the residues in
total SELEX RNA sequences. In SELEX RNA A04, the constant regions decrease
binding compared to an equivalent RNA without the constant regions. However, in
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SELEX RNA B07, there is roughly a ten-fold increase in binding when the constant
regions are present compared to when they are absent (Figure 5 and Table 2). In the case
of SELEX RNA F06, the constant regions only marginally affect the binding affinity to
MBNLl. The constant region may be setting up a preferred secondary structure for
binding by MBNLI in some cases, or blocking the binding site in other cases.
Reasoning that MBNLI binds a motif shorter than twelve nucleotides (the length
of the long motif) and the fact that 5'-YGCUU-3' is highly enriched in the SELEX
sequences, 5'-YGCUU-3' was used to search for potential MBNLI binding sites in pre-
mRNA targets. Three potential binding sites were identified, two in MBNLI and one in
SERCAl, each within 200 bases of intronic sequence flanking exons regulated by
MBNLl. One proposed mechanism for how MBNLI regulates alternative splicing is by
binding upstream of the regulated exon to promote exclusion of an alternatively spliced
exon and binding downstream to promote inclusion. In total, 6 pre-mRNA MBNLI
targets were searched and 5 contained 5'-YGCUU-3' in the immediate 200 bases of
flanking intronic sequence (data not shown). All pre-mRNAs but one followed the rule
that the potential MBNLI site is located downstream when MBNLI promotes exon
inclusion, and upstream when MBNLI promotes exclusion. The SERCAI site
potentially folds into a similar weak stem-loop as the cTNT binding site, both containing
at least one pyrimidine-pyrimidine mismatch (Figure 7A). The MBNLI site in SERCAI
is 135 bases downstream of the regulated exon and MBNLI promotes the inclusion of
that exon, which follows the rule (23, 24).
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MBNLI binds two possible sites in MBNLI pre-mRNA, one 75 bases
upstream of the regulated exon 7 (site #1) and one 179 bases upstream of exon 7 (site #2).
These two sites flank a predicted polypyrimidine tract and branch point sequence. It is
possible that binding by MBNLI to the two sites blocks binding of splicing factors SFI
and/or U2AF, which would promote skipping of exon 7. Alternatively, bound MBNLI
doesn't allow bound SFI and bound 65 to recruit other splicing factors because the sites
overlap. In addition, a FOX-l/2 binding site (5'-UGCAUG9-3') overlaps with the
potential MBNLI site of 5'-UG9CUU-3' in the left side of the stem (Figure 7A). FOX-
1/2 and MBNLI may work together to regulate the splicing of MBNLI 's exon 7, as
FOX-l/2 has been generally shown to promote exon exclusion by binding upstream of
regulated exons (4). In addition, the yeast protein RPL32 binds a bulged stem-loops
structure in its own transcript that is thought to block binding of Ul RNA. This blocking
event inhibits inclusion of the downstream, regulated exon (25). It is possible that
MBNLI behaves similarly to FOX-l/2 and RPL32 and blocks binding of essential
splicing factors. In vivo binding studies are under way to determine if the three, novel
MBNLI binding sites are required for MBNLI alternative splicing regulation of MBNLI
and SERCA 1 pre-mRNAs.
Identification of additional MBNLI binding sites in pre-mRNA targets will be
very useful for understanding how MBNLI regulates alternative splicing. Our results
should help in the search for novel MBNLI sites; however, with both a structural aspect
and a sequence aspect, MBNLl's binding sites may be degenerate and challenging to
recognize in a sea of intronic sequence.
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CHAPTER IV
CONCLUSIONS AND FUTURE DIRECTIONS
The muscleblind proteins function as alternative splicing regulators and are
involved in the disease mechanism of myotonic dystrophy (DM). They likely regulate
alternative splicing by directly binding pre-mRNA targets, such as cTNT (1, 2).
However, little is known about their RNA binding specificity. The human protein,
MBNLl, co-localizes with aberrant CUG repeat and CCUG repeat RNA in DM type 1
(DMl) and DM type 2 (DM2) patients, respectively. Muscleblind becomes sequestered
to these aberrant repeat RNAs in the nuclei of DM patients, forming nuclear foci (3-5).
This sequestration event removes muscleblind from regulating alternative splicing,
leading to mis-splicing events and disease. Mis-spliced transcripts include cTNT, IR,
CIC-l and a handful of others (reviewed in ref 5). Aberrant fetal splice products of IR
and CIC-l are thought to lead to the DMI symptoms of insulin resistance and myotonia,
respectively (6, 7). DM patients experience a multitude of symptoms, however, only two
symptoms have been accounted for from mis-splicing events. There are likely many
more undiscovered links between aberrant alternative splicing events and DM symptoms.
Less complex organisms, such as Drosophila, have a single muscleblind gene that
contains two zinc fingers, while more complex organisms, such as humans, have several
muscleblind genes with up to four zinc fingers (8). The zinc finger domains bind RNA in
80
a specific fashion (2, 9). Muscleblind-like 1 in humans (MBNLl), binds CUG and
CCUG repeats in their double stranded form, not as single stranded RNA (10, 11). In
addition, mutational studies on CUG repeats show that MBNLI prefers weak double-
stranded RNA with pyrimidine-pyrimidine mismatches (2). MBNLI binds a weak stem
structure in cTNT intron 4 and promotes the exclusion of downstream exon 5. The stem
has characteristics similar to CUG repeat stem-loops; both stems include pyrimidine-
pyrimidine mismatches interspersed with G-C and/or G-U base pairs (2). Despite the
identification of a handful of pre-mRNAs of which MBNLI regulates the splicing, no
other binding sites have been identified. A deeper understanding of muscleblind's RNA
binding specificity will allow a complete list of muscleblind regulated transcripts to be
identified and provide important information for understanding muscleblind's alternative
splicing mechanism.
CONCLUSIONS FROM CHAPTER II: RNA BINDING SPECIFICITY OF
DROSOPHILA MUSCLEBLIND
As mentioned previously, Drosophila have one muscleblind gene (Mbl) with
splice isoforms that contain two zinc fingers, the RNA binding domains (8). Mbl
regulates alternative splicing, like MBNLl, and Mbl regulates at least two of the same
MBNLl-regulated transcripts in Drosophila, Tnnt3 and Tun (ZASP in humans) (12, 13).
Drosophila has provided a useful DMI model that has phenotypes representative of DMI
symptoms (14). In addition, MBNLI and Mbl are functionally conserved as MBNLI can
rescue Mbl knockout phenotypes (15). Drosophila muscleblind simplifies muscleblind
RNA binding specificity studies due to the lack of complicated gene families and high
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levels of splice isoforms. Therefore, SELEX was performed on Mbl to determine
Mbl's RNA binding specificity. Binding studies were also performed with Mbl on CUG
repeat RNA, the toxic RNA in DMI.
Co-localization of Mbl with CUG repeats is observed in the nuclei of the
Drosophila DMI line expressing 480 interrupted CUG repeats (14). To confirm that Mbl
binds CUG repeats, and to investigate which nucleotides it interacts with, in-vitro binding
studies were performed on a screen of CUG repeat mutant RNAs. From this screen, it
was identified that Mbl is a highly specific RNA binding protein that requires a
pyrimidine-pyrimidine mismatch in the U-U mismatch position and does not tolerate
changes in 5' to 3' direction, flipping of C-G base pairs to G-C or complete Watson-
Crick base pairing. This specificity is similar to MBNLI 's specificity; however, MBNLI
has decreased binding to some of the aforementioned CUG repeat mutants while binding
by Mbl is completely abolished. This indicates that Mbl follows a similar binding trend
to MBNL1, but is more specific. In agreement, Mbl binds an MBNLI binding site in
cTNT pre-mRNA (32 nucleotides) with high affinity. The cTNT binding site forms a
weak stem loop resembling CUG repeats in some aspects (2). When the base pairs
forming the stem are mutated such that the stem can no longer form, Mbl binding is
abolished, while binding by MBNLI decreases by 100 fold (2).
SELEX was perfomed on Mbl to determine structural and sequence elements that
Mbl recognizes in order to bind. After six rounds of SELEX, 25 sequences were
identified and grouped into two main groups, sequences containing 5'-AGUCU-3' and
sequences that don't. Of the SELEX sequences tested, the group that contains 5'-
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AGUCU-3' bind Mbl with high affinity and the group that doesn't contain 5'-
AGUCU-3' bind Mbl weakly or not at all. Structure probing was peIformed on a SELEX
sequence, SELEX RNA 20, that contains 5'-AGUCU-3' and was determined to fold into
a two stem structure with two single stranded tail regions. Footprinting analysis showed
that Mbl binds three guanosines (Gs), one in the 5'-AGUCU-3' motif, one in a loop
region and one in a single stranded tail region. Mutations to any of these three Gs
abolished binding by Mbl, indicating that the Gs directly interact with Mbl and/or set up a
secondary/tertiary structure necessary for binding by Mbl.
Truncation and mutation studies peIformed on SELEX RNA 20 reveal regions
that aid in binding by Mbl. The two single stranded tails are necessary for high affinity
binding by Mbl, and when removed or mutated, binding is decreased significantly.
Removal of either of the stems or truncation of one of the stems significantly decreases
binding by Mbl. The only truncation that does not affect binding by Mbl was shortening
the 13 base pair stem to a 4 base pair stem. Taken together, this information indicates
that structural elements and sequence elements are both required for tight binding by Mbl
to SELEX RNA 20. Interestingly, there is only one obvious pyrimidine-pyrimidine
mismatch in SELEX RNA 20, and when mutated to form a Watson-Crick base pair,
binding was decreased. This preference by MBNLI and Mbl to bind pyrimidine-
pyrimidine mismatches in a toxic RNA target (CUG repeats), a SELEX identified RNA
target (SELEX RNA 20) and a pre-mRNA target (cTNT), indicates that MBNLI and Mbl
binding sites in pre-mRNA targets may be similar.
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FUTURE DIRECTIONS FOR CHAPTER II: RNA BINDING SPECIFICITY OF
DROSOPHILA MUSCLEBLIND
Both MBNLI and Mbl bind RNA in a specific fashion; however, it is unknown
which amino acids confer this specificity. The first two zinc fingers of Mbl and MBNLI
are highly similar in amino acid composition, with some key differences. These could
account for the difference in specificity, as Mbl seems to be more specific than MBNLI.
It would be interesting to change amino acids in MBNLI to make it more like Mbl and
identify residues that are responsible for Mbl's highly specific RNA binding properties.
For example, one could replace the asparagine in MBNLl's first zinc finger to the
arginine found in Mbl in that position. This would be replacing a small, non-polar amino
acid with a large, polar amino acid. In addition, it would be interesting to see if changes
in spacing of the CCCH in the zinc fingers playa role in specificity. Mbl' s zinc finger
one is two amino acids shorter than MBNLI ' s zinc finger one. Instead of making
changes in the RNA to identify muscleblind's RNA binding specificity, this project
would be looking at it from the perspective of the protein.
MBNLI has been challenging to crystallize, most likely because of MBNLl's
unstructured nature (2). Mbl is a great candidate with which to attempt crystallization
studies as the portion that binds RNA is small, only 105 amino acids and contains only
two zinc fingers, not fouf. Obtaining a crystal structure of muscleblind bound to RNA
would greatly help the DMI field and the alternative splicing field. A crystal structure
would provide information on which nucleic acid residues Mbl interacts with when it
binds. This knowledge would give us insight into Mbl's preferred RNA binding site
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motif. For example, does Mbl directly interact with pyrimidine-pyrimidine
mismatches or the backbone of the RNA? With Mbl and MBNLI having such similar
RNA binding specificities, this information would help to identify both MBNLI 's and
Mbl's binding sites in pre-mRNA targets. This would help to complete the list of
MBNLI 's pre-mRNA targets and broaden our understanding of how muscleblind
regulates alternative splicing events.
CONCLUSIONS FROM CHAPTER III: DOPED SELEX WITH MBNLI REVEALS A
MOTIF USED TO IDENTIFY NOVEL MBNLI BINDING SITES
MBNLI regulates the alternative splicing of cTNT pre-mRNA, along with several
other pre-mRNAs (5). cTNT is misregulated in DMI patients due to aberrant
sequestration of MBNLI. MBNLI binds a weak stem loop structure upstream of cTNT
exon 5 and prevents the inclusion of exon 5. The weak stem is composed of G-U and C-
G base pairs and two pyrimidine-pyrimidine mismatches. The loop is composed entirely
of pyrimidines and is proposed to be the polypyrimidine tract that the splicing factor
U2AF binds (M. Bryan Warf, unpublished results). MBNLI interacts with the stem,
however, it is not known specifically which aspects of the stem it is recognizing in order
to bind. Doped SELEX was performed on MBNLl, using the cTNT binding site (32
nucleotides) as a template, to determine what structural and sequence elements MBNLI
recognizes to bind.
Five rounds of doped SELEX were carried out and 82 clones were sequenced. In
general, there is selective pressure on most of the 32 positions toward uracil and against
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adenosine. In addition, there is strong positive selection in the 5' randomized region of
the SELEX RNAs toward a 5'-CCNNCUNUG9CUU-3' motif. This region correlates to
the left side of the stem of the cTNT binding site. Four positions out of the
aforementioned 12 nucleotide motif, 5' -G9CUU-3', were selected to remain the same as
cTNT wild type sequence, while the other positions selected to change away from the
original pyrimidine in the wild type sequence toward the other pyrimidine. From this
information, the 5' -YGCUU-3' motif was identified to be a potential binding site for
MBNL1. An analysis was performed to identify highly enriched k-mers in the SELEX
sequences and UGCUU was the highest-ranking k-mer, based on Z-scores.
The majority (78 out of 82) of round 5 SELEX sequences contain one to several
5'-YGCUU-3' motifs. The cTNT wild type binding site contains one 5'-CGCUU-3'
motif in the 5' half of the randomized region. Over half of the SELEX sequences
contained the motif in the same location as the cTNT binding site, in the rest, the location
changed. Of the 16 SELEX sequences tested for binding to MBNL1, 14 bind with high
affinity (Kd ' s ~ 37-0.9 nM) and two bind weakly, with a dissociation constant of> 1.2
JIM. The two that bind weakly do not contain a 5'-YGCUU-3' motif, while 13 out of the
14 that bind tightly do contains 5' -YGCUU-3'. This indicates that the motif is most
likely playing an important role in binding by MBNLI. To determine if the 5' -YGCUU-
3' motifs are playing a role in binding by MBNL1, mutations in the motif were made to
two SELEX sequences, F06 and E12. In both cases, the mutations reduced binding by
MBNLI significantly (25 fold decrease for F06 and 5 fold decrease for E12). This
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indicates that the motif is promoting binding by MBNL1 by providing a necessary
sequence or by setting up an important secondary or tertiary structure.
To determine if 5' -YGCUU-3' is an endogenous MBNL1 binding site, pre-
mRNA targets regulated by MBNL1 were searched for the motif. Three potential
MBNL1 binding sites containing 5'-YGCUU-3' were identified, two in MBNL1 and one
in SERCAl. The two MBNL1 sites are 75 and 179 bases upstream of the MNBL1
regulated exon, exon 7. MBNL1 promotes exclusion of MBNL1 exon 7 (16). The
location of the two bindings sites is consistent with the model that MBNL1 binds
upstream of a regulated exon to promotes exon exclusion, and downstream of a regulated
exon to promotes inclusion of that exon. Also in agreement with the model, the potential
MBNL1 SERCA1 site is 135 bases downstream of the exon of which it promotes the
inclusion (17). MBNL1 binds all three sites (40 nucleotides each) with high affinity in
vitro, comparable to the affinity of MBNL1 for the cTNT binding site. The sites have the
potential to fold into stems containing pyrimidine-pyrimidine mismatches, similar to the
cTNT binding site, but experiments should be performed to determine their structures.
The two potential MBNL1 binding sites identified upstream of MBNL1 exon 7
flank a putative polypyrimidine tract and a branch point sequence. It is possible that
MBNL1 binds the sites and blocks the binding of U2AF and/or SF1. This would inhibit
recognition of exon 7 and cause skipping (exon exclusion). In the case of SERCA1,
MBNL1 may bind the potential binding site downstream of exon 22 and recruit important
splicing factors. This would promote the recognition of exon 22 and include exon 22 in
the mRNA. Determining the potential mechanisms for how MBNL1 regulates the
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alternative splicing of MBNLI and SERCAI pre-mRNAs would be of high interest to
the field of alternative splicing.
FUTURE DIRECTIONS FOR CHAPTER III: DOPED SELEX WITH MBNLI
REVEALS A MOTIF USED TO IDENTIFY NOVEL MBNLI BINDING SITES
The identification of three potential binding sites of MBNLI in MBNLl-regulated
pre-mRNAs is an exciting start to a long journey. First off, other potential MBNLI
binding sites containing 5'-YGCUU-3' need to be tested for binding by MBNLl. Further
experimental exploration is needed to determine if MBNLI regulates alternative splicing
via binding at those locations. Also, it is possible that the location of the binding site
does not dictate if the nearby exon is included or excluded; this should be analyzed.
Assuming MBNLI does bind and regulate alternative splicing through these newly
identified binding sites, this would provide valuable information regarding MBNLI 's
RNA binding specificity. Structure probing to determine the structure of these sites and
footprinting analysis should be performed to analyze which residues MBNLI interacts
with for tight binding. Additional information from round 7 SELEX sequences may also
aid in identifying important residues for binding by MBNLI. The small handful of
MBNLI binding sites and high affinity SELEX sequences could be compared and a more
accurate consensus motif identified that takes in to account structural elements. With this
new consensus motif, the entire human genome could be searched and used to complete
the list of MNBLI binding sites. This will open up the possibility of linking MBNLI
regulated splicing events to mis-splicing events in OMI patients. This would potentially
draw additional connections between symptoms and mis-splicing events.
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Information defining MBNLI binding sites in pre-mRNA splicing targets
would allow for more in depth drug design. Currently, the Berglund lab is setting up a
screen to screen for drugs that inhibit the binding of MBNLI to cva repeats. The idea is
to release MBNLI from binding the toxic cva repeats in DMI patients and allow it to
properly regulate alternative splicing. However, one major caveat is that if the drug also
binds MNBLl's pre-mRNA targets, then it would prevent MNBLI from regulating
splicing properly. However, with more information on the specifics of MBNLI binding
sites, the subtle differences between MBNLI 's binding sites on cva repeats and
endogenous targets could improve drug design. Drugs could be designed to bind only
cva repeats and not endogenous targets. However, without more known MBNLI
binding sites, this is a challenge.
MBNLI 's alternative splicing regulation of MBNLI and SERCAI pre-mRNA
should be analyzed in depth. Does the location dictate if MBNLI exon 7 is excluded or
whether SERCAI exon 22 is included? Does MBNLI promote exon inclusion by
recruiting splicing factors or prevent exon inclusion by blocking splicing factors? These
questions need to be answered to begin to understand MBNLI 's mode of alternative
splicing regulation. Very few tissue specific alternative splicing regulators have been
fully characterized, understanding MBNLI 's mechanisms would significantly help to
advance the field.
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APPENDIX
DOPED SELEX ON MBNLI REVEALS ROUND 7 SEQUENCES HAVE
MULTIPLE 5'·YGCUU·3' MOTIFS
Doped SELEX was performed on MBNL1 using a known MBNL1 binding site
(32 nucleotides) in cTNT pre-mRNA as a template (Chapter 3). Seven rounds of SELEX
were completed with tight binding of MBNL1 by round 7. 76 clones from round 7 were
sequenced and aligned based on sequence identity using the Jalview dendrogram analysis
tool (Clamp '04). The alignment reveals 2 main groups (Group 3 and 4) and 6 small
groups (Groups 1,2 and 4-8) (Figure 1). The wild type cTNT binding site sequence
groups with Group 3 SELEX sequences the largest group. Group 3 contains two main
regions of high sequence identity: 5' -GCUU-3' in the 5' half of the randomized region,
and 5' -UCCGCU-3' in the 3' half of the randomized region (Figure 1B). The 5' -GCUU-
3' consensus motif is also found in the cTNT binding site, indicating that MBNL1 most
likely selected to maintain those four bases of the 32 nucleotide binding site, presumably
in order to bind with high affinity. MBNL1 binding studies will be performed in order to
determine if 5' -GCUU-3' is important for binding by MBNL1.
Round 5 SELEX sequences showed a strong selection for single or mutiple 5'-
YGCUU-3' motifs in the majority of sequences. After two additional rounds of SELEX,
round 7 SELEX sequences show that every sequence but two sequences contain the same
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5' -YGCUU-3 motif. Many contain a shift in register of the location of the motif
(Figure 2). Most Group 4 SELEX sequences contain a second 5' -YGCUU-3' motif just
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Figure 1. The 76 SELEX sequences from round 7 fall into two main groups. (A)
Dendrogram showing the 32 nucleotide randomized region of the SELEX sequences
aligned based on sequence identity. The wild type cTNT site is included and groups in
Group 3. (B) The sequences ordered based 011 the dendrogram in (A), with darker blue
representing higher sequence identity. The consensus at the bottom indicates the overall
consensus sequence. The 4 nucleotides unclerli ned are a potential 5' -GCUU-3' consensus
motif.
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5' of the location of the original 5'-CGCUU-3' motif in the cTNT binding site. This
new register of a highly selected motif may indicate selection of a secondary structure as
well. This is yet to be determined and requires binding affinity assays, structure probing
assays and/or footprinting assays, however. It appears that MBNL1 selected for similar,
if not identical, sequence motifs in round 7 as it did by round 5. It will be interesting to
see if MBNL1 selected for the same or different structural elements in round 5 as it may
have in round 7.
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Figure 2. Round 7 SELEX sequences group based on where 5'-YGCUU-3' motif is
located. The groupings are based off the dendrogram analysis in Figure t. The 5'-
UGCUU-3' motifs are highlighted in green and the 5' -CGCUU-3' motifs in pink. The
top of each group contains the endogenous cTNT binding site (labeled WT) for
comparison. The cTNT binding site contains one 5'-YGCUU-3' motif highlighted in
yellow,
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